var title_f30_13_30928="Pathologic skin picking 2";
var content_f30_13_30928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acne excori&eacute;e",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 13-year-old girl picked the comedones on her forehead, resulting in chronic erosions. Some of the erosions healed with scarring as new lesions appeared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30928=[""].join("\n");
var outline_f30_13_30928=null;
var title_f30_13_30929="Starting position for straight leg raise";
var content_f30_13_30929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Starting position for straight leg raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAc8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyiSSTzXyzdT3pBI+Pvtn6mklP7xh70d+1ZFDhK5/jbn3pRI+fvN+dMAJ/OgsFG5ug60wJfMkx98/nR5kgH3mz65NS6LELhDPMCyMeB6Cm3AUXEgjGEzx7Uk7mkqbik2N8x8/fP50vmvjO5vzpo/WgDIBGKZmO8xuMSN+dOEj5++351Gfc4p2OCT+NAxwkf+8350b3HIZvzNNA5OaXvQA/zGxwzce9Adv7zc+9Nxz0NL+tADt75+834GjzH/vtn603v70pxnp+VADvMf8AvN+dJ5kn99vzpM8nqPrS85xQAF3z95s/WgO+OXYfjQBxSe1MBwd+u5vzpC7jPzt+dG3jP+TSjvx0oGHmP13N+dL5j9dzfnSYwOO/alA549KLAJ5jjozdfWk8x8/fb86cRTcDjvQAGR/7zY+tL5j9NzfnRgfT+lGOtAhfMfP3mP40eYwAwze/NIcA8UhHNAxd79dzfnRvcH7x/Ol28cUm3pjpQAvmN/eb86TzH5+ZvzpOvJ60UWAXe4P3mP40nmP/AHm/OkJ4oyPxoELvcjO5sfWkLv8A3m/OkpKAHb3x99vzo8xz/G350z6UnegB3mP/AH2/Ok8xyfvt+dNPFIc0wHbm/vt+dJvb++350w570n1pAPMjgcO3500yt/fb86aaYenFMRKZWyMO3vzSGVv77Z+tRHOPXNNIHrQBKZW/vtn600yOON7fnUeKMikA/wA2TP32/Ok82Ts7fnTSfT9KQsMcjmmA/wA2Q5+dvzpPMc5/eN+dMJHemlvTigCTe/8AeP50hkkBOXb86jyc8GkLUCJfNfrvb86taRK39pQDew5b+I/3TWd9at6P/wAhOD6t/wCgmgCSQYkb3JoAz0HXv6U6X/XP/vGjI25yKkYY5qC5/wBXj1yKsDjgnmoLshbdmP8ADzSew0a3hRle1C+gxTtShw7uijCYBx6HpVLws5RcNgbucVtX0AkRiO47VL0Z2Si5R1MMY7/iKXGQO2aAemecClz09as4w/lSjjpkD0pM8e2aXnuBQAH+dKRxn9KTg0c9e9ADuOM5+tHIHNAPrSg8cCgA6dqAeM0flR/FTAMgHGKM9s0uPWj1IHFAAOcelIRzTxg9PTpSdOuMUAIeKUd/WjgnPahQD0z/AIUDEHWlOM0pB6j8aMHBoAQdKD3pR1FGOPagBpxjigDOKUrg4peOmaAEH6Uc5waU/Q0dunNADexo+v507OByKQjAwDmgBD1ORSAc8il/nR3xQA3Ax70nbntThweaCKLAMOc5oPTmnEccUlAhmOKQ08ikIOM0ANI560hOKd0pCOaAGMDim9elSbc03BpgMNNYc08g8UFTSAjwAPWmnjmpCMUmPSmIiJx3pGPNSlaQrigCIk0096l200rkUAM78UmM08ikNADelIc4FPxSFT3BFNJvZC0Izk9KuaPn+1IAf9r/ANBNVSPerekc6nB/wL/0E0WAllwJWwOMmm447+uf61NKvzyf7x/Cm4x24/nUjG88AdemP6VT1PP2c46YOavYHByDVe/TdHkDODyKljRY0EBhGc+1dSsYZTjiuL0OfypDE3VTiuytZ1kQY60md0ZXRi6hbmORnUcZ+YDt71Uxzx1rormISEmsW5t/LJKn60KXcwqUuqIMHJpQPypcFjkgc0vb6VZgN68GlxyP6U4EdBijuO/egBoPHNO7YJyaUADgfWgDHHegBoOOacR7dqUDkc/hTgMkdfwpDGdCPpSjP4U4Aj60uM+/amA0ryPyoJxTh69/ejHv9DQAEYoxjHOKfgH14PSg+gGO+aYDMfLz1xRj1yafj8qMfnQFhmBgfzoKgZGcincf/rowc8GgBNvSkwDgZFL/ACpBwKQCegpO+MflTjnPTjpQRyKAEIzmkI96ccenakxj8DQMTAxzQQMmlxjt19KXn0pgMxyec0mP/rU4DnpRjjgcUCGGgjkU8jnmgD86AsM2nj19qTHNS45A/GkIHT0p2Ai28UbeKkwTwKAhOOgrSNGctkZupGO7IccUY4qbyx3PPtS7Fx6/jW8cFVe5m8TBFbb+VAU9ACanCqO1BPIx0NbRy9/aZk8YuiK5Q9MHP0o8p/7jVO7k8dqRidp5/Kr/ALPj3I+tvsQGJs/dbj2pNny7nIX60pZhkbiKifL8M7NVrL4LdkvFyeyJEi3pkHg+1Els8fVCV/vAZBqaEDYpXsenqO9W4rgiLaOtN4GnLbQFipLfUx2XBx0PvTGHsST0Aq7c3DNJ5UYJcruPGcf5warjAiw+4Sn17/SsVl95aPQt4uy2LVrZsF3tjd7c4p9+CFjbFQJHIkQdCwJGTg0PIzxjLnPoecV6FOiqa5YnJKo5u7G+UGAwR0qzpCRNqMONjct0OD901SWTY37w7T2I6Vd02KKbU4D8rN83Tg/dNEqSa1CNSSejGyA+a/oCf8ikxx79KlkGZWxnlj/ke9Nx6c9wf8/yr5s9gaMYA/L60jIGUrgEEYxipFXBwf8AI/wpxBzwc8U7DOdvA1rdhgSMHGPat/TL75FIJPfrVLVrbzIy64yOD/Ss3T5TGxjYkEHis3oa05dDu0mEqgg8mmXEeeMdayrK5xitmB1kU+1KxumZ1xbrjKD5xVTjHTjpW48SvxjJ9qo3FmwY+V19D3pp2JqU76opAc+1O9M9BT2QocMpB9DQFyBt9eM1ZzWsMA5pQvPXnNKB6Hp704rgc8UAR9gec+9Cqeop4UngGnc5wMUAMIz0/SnEZGPUY6Ud89O3NKB7H/GgBB6ikPHbmnheDzTto6d80AMAwDjpS4J6daUYPTgdBSgZPPH0oGNPtzzSge3Pal5OMYpTnj2oAZjngfjRTgOMnvS4IAyRnGTQAzHPBo+8e/0p+36f5/8A10dj9aAGdhjHWkx27U7GevJpk00UK75XCjGcmgBSpAz146e1Ru6IuXYKPrWXNq7TuUs1IHTeadbwMx3SksSeSeTUOZpCm5Ft72AHglj7Comvn52wHHv1NTRwLn7o460y7IHyoOannZsqC6kB1REx5kTKfY5FMOsx5G2FiPrTFtC7ZI5+tSx2aLw360c5HsRrax2WA/iajl1aZuEhA+pq2LVcHABNKtqD1UU+Zj9iRaNdzzzyx3QGcb0/kR/KtEHBbB4PINVWgSF0kA+ZTk8djwf0NW1TcGB+le7lrVSm090ePjoOnU02YnQg9qUnv6Uh5iDg5Ujn2NIkqpLEjso80lVz3PtXocqSucN7gTxSE9+1WZ7JwrMmMDkgnpSR2kjNtcqh6c85p6BqQAbhkflUY+9jHStSKyjjBLM25Rzu4H1FSy2sKkFUHze1Cs9g2MSdcDpxQhBiraMEZIzGhP0FAkVT5YVQDxjFNRuK5zzgKdz8CoXbJIQACt+a0gmJDxqrE8MpxVRNO8q4VzIPLB6EYOaHEEyku6OJVQFnPOMdPahY5m+8+OegNas1oqH93LC49Acf/rqvMF8vAxjp6VOttBlTTom2ySSZYSE5POdo4H6fzqneSz6fMyOhntjyu8ZyPrXQxuskAidgoUbe3FVJFZV2yGMxAfxH/CtIpWsS3dlC0vYph/os5ibvG/Sp513KTJH5b9dy8qf8Kx9Z09YSlxY4wwyVzUNlqssJGGPHVWpNcrHa+xplTyOCtWNLQpqUJXOMt/6CajS9tbnBf9zIe46E+9XtOiK6jblsEHJDA8H5TSkroSL2q2gindhwC3UdG/wNZxHPByf8/rW1PI+XWUKVLEEVmXNu0J3xnKH+DPI+lfIxl0Z9NVpX1iRqcHK4xnI/xpVyW9O//wCr2poYEHBB+n+etOVec8nvWhzibdwG5fl6EY7f4Vzup25tLkOudue/UCulJwDjHsR61W1G2FzblSPmxkHuP/rVMkNOxVs5AUBHSt2wkyetcpp8hVWib7y8H3rf0w/dz1NSjqTub8RGeuKbdAKoJFPjUEA/qaiuSGQjdUs0RnzTKxIYjFVX3DlCNvoeavRWysSSM471I0IJPGAfSizQOHNuZBudjfMhHfK808XcDEAOMn1PerUsSqGyA1Z7WyOSzDFPmZk6C6FtcEfKwPt2pwUk5x2xWU9qEbcpI96jxKDhJZMfXinzk+xZtHHp+NGOO/JrDKz95n+m7FIVmBwZpfwajmF7Jm4WUBcso75JFRmeBACZUH1PWsQ2+7khiPc09baFRmUfhRzgqTNQ39ohA89PoKifVbVehZvoKpeXFj93GAPUijbkYAGPelzMfsi02rxDO2GUjtzUD6xMSQtvgdsmo1EK8EhT6Zp6yRKMKFH40uYPZoa+p3R6RIoPrTW1G7LZJAI/uinAIckN83qDTsKBy4z7Ucw/Zoh+23znCuFpPtd4oI+0cj0FSMEPX+dI0aN8oY/SlcfIijLcXLgk3Mue+DgVWW3nu5UiQtJJIwVVzkkk4ArUFqo98981R1MtZm1uYC4khmWQAdTgg1S1YOKSuehaF8OJFCtqF8qnPMcC7vw3HH8jUfjDR4tCv4YYdywyQh8u2TkEg/0/Ou1uPECRxRrpVu91I/QojMq+5I/kOaybqCe7mW4u9PurqdM7QYQqJ9AT/PNdMqatZHNCvJSuzhollmG6COWX/cQkCmLEwlKyBlk7q4wfyrr72/1W0XcmlXSqPSHcP0qrZeItK15vsGsW/kXfIjlIK4Psf4T7H/61Z+xRp9ad9TBSHBzhj2yBxUxTuF4rptC0Nkvrm0uwl0qhZIJ8YLocjB7ZBHb1rbl8PwrERFaJu65xk1awravcbxcV0OCgti7qscZdm6BRkmhrU+YdwIccbdpyK9I03R2hAZ0Cn0AxXCfGaymgtbS+geSNS/lTBTgNkfKT+RH41f1XTRkfXPIpiz84iNdpJyDz+H4VoReHrzHICn65ry/w/qDaZrNvdbjsDASjP3kPB/TmvprToVntI3GCCvX1rowzdC6j1OSvNYi3MtjzhPDdyoYb12k5xj8xWF4g0K+sPKvBGZ4IA5dIz821lIOAeuOte1taLj7tUL2yEkZBXiun6xN6NmKpRWyPM9GvI9S0+CeNlZmVQ65+62OQfxqSSMhhuUkAEE+oHf8ACszRdH/srW9bgjkBGVby1GNilm2gn6E/hWpIX2P1AA4r0MPFzp3Zw1WoTaRFqLKtuFDEls4x1FQxSkwn7xOwSDPT0P8An3qPU2LMncMBUyp/pCI3RYcHP411RpqMTFyuyYP5Vr5hI3E/dz1qtbxNI285znOfX2FF03mMka9jwK0oItqKpHseaLWQXuVxyuMfrVW+b5Rj1rRKgjKn/P8AWs68BD4OBg9u/wBKUUNsoNwD+tRwQedId7Yxk/Spyu4Zx0pinYwYdqGA82Zx8rAn0x0+lEMO1mLYB7Zqym1wNpHAp7IcZYbl6ClYLlMxrLIVKIc9SR0/H+tVZtFt3kJKnaf4hwQf6ir6jZIpAO09farcIicgq4PPIPp/9alcaOcGgsARFMrJ1BPFbHhuzmtdTiR3EsDE7lHIztOK0msY84UkDPH9M0+ztpIr+Hy2JwW/kamSbRSepbu4gWdiBnJ5xVMoI2ACKCfUVfYEzNn7gJzTHRXkJIyO3sa+OSPrbmRc2olkyPlf+8P61UkV4XCyrsyc5HQ/St8w564OOeKJLaOSIxuu5D29KE2iZ04yXmYCp1z35/8Ar0DueB3wKlntJrViFJki7eopoIbgnJx06VopXOWUJR3Oe1OL7PqCtGMLKM4A4/Cug0uMbVzWZrYAa1fnG/HTj/61bOlYwpXmo2Z0UVdGymEAHt3qrdKBk1dKA4zyagliGMYwaTNLGWty8DgqMinjVAGHmRsB7UtxbsAapNkOR1qbjuXTLHJll7+vFVWGSSKh6HOTSB8HBBB9KAuI4PI4NQNHg5HfrxVlnB4xgimnBGc/hiqsIrFdxGSc+lNKcHBOPTvVjbGwPr+tIy4I+8R64pWEVRGxPGRSGNycs4H61ejidtxETso5yEZhihW3ttVhn0XqafK+wtCh5Dk4ALGke3kC89PStyLSL6YDZY3BU9whAP51fh8Oai2C0AQersB/LNUqM30Jc4rdnICzlJO5Bj0p62bdBESfWvRLXwXdum+e5ijUc/cLY/lSLpHh2AO0+q3N2UOCLS2ZwfphT/Or+ry6mbr011OCXTZZCAqZJ7AVYi8PXjD5IZPzwP1rttCbR9S1h4NH0/UYntkzJNeKULhjgBVyfQ811i6YQOEX8q2hhl9oxlidfdR5VB4Vv2HztDGD6kmppvCy28DO99Ckp4Xd8qk5wBnPU/SvURpbtwEFQahp0Fisd7qcsUVrbHzCz8AEdDmrdGnFXsZ+3m2cJoHgq4vWEtxIEgzwVBy3buBj8q7vTPD2n6Yg8uBTJ3Zhkn8a5TU/ihpMMohsIJ50zzKPkUf1P5CuT1D4m61csfIFvbIT/Cm44+p/wrBQl9lWKlWT3Z69fahHZoeVBHRQMn8hXD634/ls5mihAVhzmU4/8dHP54rzLUde1TUSftd9cSKT90NtX8hxWWep29K0jQ/mZjKv2R6OvxT1WKUEQ2k0fferKfwOa1IvFvhTxRELbX7P7FcN0lcDGfaQcj8eK8mbk5UEAde9MYrjg445B7mtFSS1Whn7Vvc98+H/AITn0nxJcBblp9Mnt90Lk8qQw4Pboeo616ilgiAY5rxH9ni+uJdT1C0knle3iiQxxs5KpktnA7dq9+2cVav1GrdCg1sPQVyvxCt7WPw1eTX1oLu3hXzmh6btvzf0ruCnFYPi+y+1aBqEOM77eRfzQirjq7AeGnxT4K1GBYNS0d7dB0xEOM+hXmvW/Ar2t74ftZbC4+0W23akhGCQOMEeoxg18oDPy+aWzgcnqOK+kPgBN5/gtYwf9TPIn67v/ZqzS5XuHNc79rUelVp7X5TxW35XrTXhBU+tXcDxnxTZLba5dSKvzTxRBv8AgJf/ABrFmP7iYdSOufr/AJ4rr/HsZTV2UKOYl5/Fq5OVc2rjBBGM47Gvewq/dI8qu/3jKWpxFZ7bP3cDlqlL4muJADwBHnPerV7EJLa36h0Pzd8DrkUyxsLrUbqCwtAjXUm6VhI5VVA65OD3Kjp1NbSkox5pGcIuTsjOt1Jn3gnaOvFXxOnkyykgqowo9TXZS6Hoei3dtpd14c1rXLxlVpryKOTy13ddgDAceg5Hck1geONDk0EXDQHzNNaRQru37xNxwFPGDg45PJB9s1yxxcJu1rHRLDSirmbGCEUOeWySPT/69V9RTAR8jn2q2ARMoPACgEY6U7UIv9E3D3rpRzmLBtZgrEAd/am31q1vg4+Q+nSmRsTcJGgGWOP1rfvolezZQCVUDkj/ADxT62A5yCTy51IJ2nqOtbYUTRggda58AxzbDn2rbsCRFkHj27f/AF6lqw0yCWLaSKrOMNnODV++bZDycHB5PoKoxPiEuwA5wAe1DVxjhKyHIkGfrV/Srt/t8S70wSx55/hNZ33h91TngHFS6e2NSgxgE57dtpqJLQaepvblMjgHDZzg96UHg5GKjvEIkZlHIJxUMc2M5zXxiZ9cXlGRkDmpBGpXuDVaOcHsR71cjZGHynmqKRWltye2aozWSMThcGt4YYDJHFI0AYZ4qWg0OO1PRjdQlFkMZB3DIzzUen+ZZShLgdP4hyK6K/8A3SHnH061izF3I8snI9am40lHY1oZleMMGWnsQVyGGKwJbfdkLuVj3U4/OqrfbowfKlyP7rU7g9TemdMYLis+YQ5JD5OaxTdXBYrMp4H8HP8AOlWe1JyzspPXeDxTSTM5VEuhcnuYY1O6QD8aqC8jklEdurSyekYLH8hUBksHvo7aYxpBIpLzKwGD257V0emaJbNEU0vxNdWobkrBcAZPvjBNaQpJ6tmE8S1okVYdJ1icB49LvFT+/Knlj82wKsafoV3cXgjd7Zh1dYLlJWQe+0nFVNS+HuqXeZI9WS9J6faHbJ/HJrpfg14cvNK1HVodStWgdli2scFXHzdCOCK6KdGDZhLE1O1jRtvCdjboZJY3lkPCqznBP4Vp2WhWsEefskZb3XvXb/YVwBgCka0RO1bpJbIwc5PdnDeI9dXwvpaXEunC9WRxCsCts3MQcc4PHFY2k67qmueVa2Ph2w0q2MqGaVJMsY88qAFHJrp/GOmQ3Mlg90QlpBI00js2AoCn/Hr9a5A/EbTk1W007SrVpInuI4fN4RQpYDIHU/pUSm+ayEl1bPUrfT0KDOTxVlLCIEEoCRWrAq7BwKk2D0rS4jKltk8tlK8HivLL3U/DtvcywS+I5InUlSI5dwGOMfdIFeyzIPLJx0r488UxSW/iLVovmEaXswHpneaznHmGpWPcPhmLW71jUmtdcfVoVSMKJFwYuW46AHP9K9OSxT0rw/8AZyK/2prKruwYYSc+uXr39Bxmq2QtyobZF6AZrz/43W+7wBen+5JE/wD4+B/WvRZT+8FcL8aOfAGqYOMBD9P3i0IHsfMeSQECjOfTk57UHd909j096Qhif7zdcg5pN3ynOd2e9UZDiMcH1oIKFhn64PFKqswIVGY57DpUbcBgRz0+lAWByUZlyPQ4OQaYzFskkZppOaQ9sUhnrn7OzH/hIdSGBxBH/wChH/Gvo9V+UV82fs7nHiTUvX7PH/6HX0qn3RSNI7Cbao6rGHtHT+8MVo1Vvh+5bNNPUGfD08Xk3MkT8+W5U4PocV7t+zbdFtO1a2bOI50kXPoy4/8AZa8W8SRC38SapF2S7mGP+BmvXv2bbW7abV7owutg3lxrKfumQbiVHrgEUTWolue8U314qUoe3NIsbntSuWeW+PkB11+Puwp/Nq5OWEiylOMBmUdfeuu8e4XxBODg4jT+RrlZJFNuVBCnzE7+9fQYb+FE8et/EZQDFo3IGWNwyRA89D/If4VveCrKNvG+mpIPMmggnmz6sF2gfTL1g3wNvnaS3kxFtwPG5vT35rpvh3q1rpviqSG9tyz3rQwrd/KfIYgjYxJyAzbOnGSM0sW2qTsi8Mr1Fc3dM1fVtH02NfEWqLqGtSxjGmWqx5i5+87gcHtk8dhuNc34rnuNW0Dw7dXixrc3NxMVWEnb5al1BGeem3n37Vsf27Zan4zk02bQdAmhlunhN8SN0u0cOrlcMx6Bc5yCM8Vi+Lb6xvNS02PTDMttYB4lZRiF4xj5Y/X5gPmHZPcV59KFprTXc7asvdepmdZGPGC3A+lSXSh7JgBn5T+NR+ZsRPu56/XPaplk3xSBgv3QOB0r1TyzjlLC8yn3lYHp9K6R7keQZVw43BXQ9x3/AArnoJBHqNwjhSTwCa04QTHN0C7Cf0q7agUtUgRW3wsWjYbkYenp/jV3SstA3PPt39hUNrF52ioGO1kyRn0JqNrmGBQFPIHRefwpPUY/VPmmIzlQDwKzvOOxl565x+FXB5kvLoy8E884rKug0cxU8UDNIECME84OOnqKn0mFpdWjAHr+e01RJEkOF+9nj1rodBhxdQsOeuT+BqJfCNbjvtAmLFTnmmSZAyOtcyzXemSs3M1sWOcfeT61rWWowzplSCD2z0r4po+uhNTWhbin+fBOD71filwODxWXKElGRw3Y02GV422scjtQmFjdaUDBU0fbT0xz7VmPPlfvc02NyDwee9ItF643S8tyPSqxt1LDjBHepInKtzk5ommwwZTgD0HNIsrtbhZmL53YwSKrTQ8nnPpz0qSWb52bB5/vd6gaXIz09OlICtPbZ6qM+mapy2W5ctgD161qK6u+1jgdttPwVJAAOe7dcU0gaRk6Td6Xot9LLq1mbq3kj2BVQNg5znDYrSOpfD3UD+9t5LRv73lMmPxXIrn/ABqFWytyowd5H6Vx+SsmYyWA5Bx/SuylG8dzysS7VGrHqttpGhSHfoHiyS2fshnH8iQa734XW9+t1freapFqcYCeVImPl+9uBx+FfNZAIGeT3yK94+EZutC8Af2tp+i3mr397fPDJHbkKY0jUBc56Dr/AN9VvCLV2c90z2RkO3pzVfymkO7HPpXGP4s8eS/8engLyx63N6n9MVXuNU+Kd0hFpoWiWGf4nnVyPzfH6VVpdgI/jjpl9P4Hllto3aK2mSWfYekfIJI7gEivnqxkMF/bH5DsnjfcOejDvX0R4esfiCuv2s/i/UNNfQfnS/g8+NVaJlIPRQOM9zXzrqBgtru8htZo5IYpnWOQEHcqsQpB9xTSaYj7StVymasharaJILnS7WcEESxJIMe6g/1rQC1L3KK0qZjP0r5I+JVu9v4611SDs+1sw9MsA39a+v2TK184/FnwV4ivvHF/daXomo3dpOI2WWGEshbYAeR9Ka12JZt/s46POF1LVnUrZzbbZCeSzoSzEe3zAfXNe6iHj5TXj3gzwRd6v4G0zQvEFnr+izWE804eJliWcO3HOSc47EDpW1F8F9BHM1zrcp9XvsfyFNrzGjvJ/IgJe6uYIV9XkC/zrl/F39h+KtHuvD9rrmmi/vUMcCi4RyZOqjAOcZHaqKfBfwjx5thcSn1lvnP8qv2Pws8MaVcxXumaRCt9bMJYGe6lwJByuTk9/Y/Skl5hc+Tbu3ls7qWC4XZcQu0ciHqrKcEfmKaJ5lOVlkVvYkV7T4k+DHifWtf1HU2u9Die9uHnaNJpMJuOcAlOaqJ8BPEb5MmqaOp9nkP/ALLVcpNjyF5ZXzvkkbPXLHn6+tR4r2ZvgHrSbfN1vSlB44SVv6VZh+AN2x/f+JLNR38u0kb+ZFKyXULM8PxzTT0r6Fh/Z7tsBpfEspzz8tmB/N6tx/s+6KD+917Um/3IY1/nmjTuFmcL+zyceJdT9fsqH/yIK+mEB21x3g74ZaH4RluLrTpb+e5kQRM9xIpGMg8KqjuBXbxp8oqWWiPFV70Zhb6VfKCopYwVwelJMZ8VePo/J8ca6uMYvZD+Zz/WvZvAtjeeIfh1oFr4P8Tf2TJYrJ9vWO3Ls0zsTyeB0B6Z616qfBvhh7h7+fQNNnvZfnkmlgDs7epznmt2Hy4YkjiSOONRhVRQoUegHarbTdybHkjeAvGz/wDNQr7/AIDbkfyaqt58MPFV4m278e6pKvcbHAP/AJEFezmX/aH51HJMMcsPzoTXYLM+eZ9Afwt52ky3st46y+a0sibWO5VPPJ4GPWq8u5o4wF2kzLgdq6H4izA+Krs53AFP/QFrn0yRGF+UiUEcZAODivoKCtTj6Hk1fjYlzH598QTmKI75Xx3HRR+X61FDZwx2d2pjVvtTl3Byd5Pr7VOy7IiFzmVtzk9c+9QyMDgL/Dxkdv8A61bOzM02tia68i3037NIiSeYApRvu4xxx7DpTrK2/crNcnCBcKPQDpxS2enmRxNc8J6N/X2qrrN7vCwQEFDx8tKy6BcZNchnPkgY/wA81ftAy2spbG4noTVO0iQNGBg9yMfrVq+mH2WQ/JgnA/KlYZxtzu+2O3cmuhYMumSSoPmddijGRyKyLOA3d47D/VhscV1piC2jR7fl2fl0/Wi+omYt0os9PjhU/wAO5mz1qpoNp9o3TuuYxyPf3p2rut5qC2sZOMDewOeP6c1vWixxW4ROBkdB0+lDGZ84fzmjiXk8buwrC1mLy5IuM846fpXSMS8srDcM578Vz2sR74yQQWU8+9A0GnqXfAGRjHNdTphEF7AjfeOfYdDXP+G0zBJLg5B2geprRhvorbVoI49s1y27IHRRtP61m9mNblZ1HnP0xnnnNU7nTY5m3xEw3HZ04z9R3q48m2R2GAxOMn/P+RTSzgbQD6jPp6fSvkLXPoVoZ4nmtnEd4BgnAkH3TV9RvGUbPtUcjI0biQK6MMFWHB+tUbeSSyl2PuMGcI55I9j/AI1nKNtTqpVb6SNKQlR0II9adYyq7HJANSxMk6jNRSWALb0YqfUVNzezRdzsYHPy1DOxwSvAP61UeC6xgXHA9qg2T+YFWcs56ADNLcfNbcsFHYn94R+NRyRsM46epqtJDqXzFWiIHXcev5VCTqSlWe13E9CrijlZHtYlxSy8YwvrUiSfKdwwP1rJkv5QczQyj3KHGfamjVYAfmbB9xRqCmu50Og6RYeIPFOn6ZqomltJIpW2xSbGLADHP516da/CnwdCP+QXcSN0Je6fn8jXlfgS/ib4h6Bh1+d3jVs9CyHA/E8V9GSSW8QzNcwRY7PIF/nXo0XamjzMT/EZyi/DPweCpXw7bn/fnkP6bq6DRdB03RUZNJ063s42OWWN22k+uCcZ4HNQ3niPw7aYFx4g0mM/3Wu0z/Os+fx94Pg4k8SWB/65ln/9BBrTnMbHUhD6RD/gNPG71Qf8BFcO3xR8FRjnWyx/2baU/wDstQv8W/BCcjUrpj/s2cn9RRzBod+yb1KuUZSMEFAQfwqNbC03ZNtZk/8AXun+FcD/AMLi8FKM/aNRPuLQ/wCNH/C4/Bj/ACo+qPgZ+Wz5+v3qXMGh6LbII8oAAFJAAGBirSgVyfhXxfpXia1lvdIkmNushiImTYwYAHpk8cit37dH/eqWM0cCnkjyFAJ78A1l/b4v71ch48+JKeD2tU/sj+0EnR5PM+0iLZtKgjBU5+8DQgO7LpnkNSh1HG014TL+0BcyNttvDlmmeA014xA+uFFZsvx/14/6vSNHjB6ZEjf+zCqFdH0SJR/cpfNP/PPivmu5+O3iwzFLaPR8Zwuy1ds/TLZqrcfHHxkxUQ3mnjIGdtkowfTkmlqF0fTvmEE/u/0oEj9o/wBK+Wrj4zeNwu1tWjimViHT7DEu3H1HXrxiqc3xY8cMrGTxDeRO2GQJDEoI9fu0Bc+qbudg0IZCMsRnHtSiSvmDwj8RPFN34r0ZNW1++uLKa6SOSOWQFGBIHIxx1HNfRRuW7moady4yVjeiFxJCGijZkzjIFOMdyBll2/XivmX4/wA93D4osZIbm4jhnsx8qSsq5V2B4BxnBFeWzTzukfmNLyCdzSMd3PXmrsS3qfb9zeQ28Dfab6ziYnO1p0BP4ZqRLxNg+YYx618Kuv8Ao7tsjIz94jnoa+rdPui2n2zGT70SHr/sikNO53pvU/vD86hlv0wfmH51x32kE/6z9aUzjB+cUDJta+JHhLRriWz1TVZkvosb4YrZ325GRyBjoQetc7e/G/wlbjEFrrV2cZDeUkYP/fTV4V8R5lPjrVz8rYkUc8/wLXPOTBNgDLLjO5Oh9MGqasQ2fQc/x50hYQ8PhvUHBJUGS7ReR9AazJfj2DA0kPhiDAbb8+oEn8gleHTNtCMQdzDcQY8fl6ii6uXZFmkyzsP4ogBgcDBx7UBdnr9zrDeIgmsNbrbG6/eeSH3hMHb1IGR8v609JNxiwSAGJHcdK7PSdI8LaL4f0xtRmsI/LtoyxnuwFLbQScZ55JqsvjPwJGwUXenqoB6WrEden3a9WnjoqCVmzilhZOTdzlWDSyhQQkajjJ6fSrStbWwBRDI6nhjwK3ZPHXgODDx3NszYwPLtHOB/3zSp8T/BuP8AXyj62bc/pTeP7REsG+rOZlee9LZcbMZIHApr2MUeBLKhAPXvXWwfEHwTfuscl3AmehuLZkA/ErgVpP8A8IbIBI1xopDcg/aU5/8AHqazCPVA8JLozgD5Fvb5jdmYd+gz7VS1dzBp8UW1TM3O0DoTXqLeF9H1ERz2ZOxfuNbyBk/DqKpt4E00uZLh7yQ5yMuAP0FWsdSI+qzPN9GZILLaq7mJ5b/Pfin3F/LKDApXnrjk4Fej/wBieGtMiAlFrGq957jH8zWYfGng7SLhoUvrQEdfs0RkA/4EoI/WoeOj9lFrCPqzhfDWn3k01zNFaTy7SBuEZIrUmM0TATK6H/aUrjtV2f4v6LaXsy21pe3cJP8ArkAQfgGIP8q29M+JPhXVYds98tsx6x3kZXH48r+tZ/X2nrEv6oraM4bUJGhtmSPjPB+lZ8QDR8tkkc165LY+GtTtjMi6fPGRnfFKuP8Ax01hO3gy0JSWbSI8dmnUn+dafX4W2ZH1WXc82W6m05JooeFkbcHH8PrW74W8O6i1zb34s5XhlBKNkEkbTzjOea2NfvfBFvam5WbTZGAyFik3k/RQT/Kua8PfFbUhe21vJp1mYxuChSykAKcdzUVMZdXgi4YWz95j5GzO553AngdetIqblztJxzk9PrVqSMb274bJOeo/pSeV8o25wwzwa+ePVIFiOAepP3gRn/P4YpskCuNsgXYefu5B/D/69XEgYhueVxwD/kCnqhBU7ycdDjHP1oZSMuKyuISBHIrJ6PnI/wAauol0AQRHx23/AP1qtKu3ghsjqB6UZYAbR0+704rPlRtGtJKxCbRpBh5sEnjaOD+NIsEcS4QEA9ic/wCfxqw2Twd3PUgA/pSnc+7nDDoOAPemlYmU3LchKZKgnPHBA6j0qJ1IBDZ45x/d/CrRHDZbCZycZ4P8zSANkD5tw5I9R9OgpkFZtz5OQx9Sw5/P+lV5bWBzholO45BZQSPwq9gYyGAxn8PbNM2AMQMHHJTpn39vrTA5q70M3upxx6eginMDyqiZG7Zydp9cHP4VzzaHqUkC3H9nXnlttBkmj2gsTxgnrmvQmYwXFpebyDBMGEik/KD8rAn/AHT29K888TW5tdbv4N7StHO43l9+V7c1vSeljnrR6kNzZy2bzW1zCsNzG+1lMgyvqCB+FFtGibJpLi2IGT5Th2zjsQB37c1Ttw8jlB5eWHBdsY78e9WbfStTuT+4srl/92Fj/StrmCQgW3DNuuHIwdpWPqfxPAomO5Y3cy7SNqsVAyBxx61rSeFdduZvMFncSM4DM0irHzjkYJq7beAddngVWtgj7s5ecYC+mADzmldFcrOeJV0kW3M/kD94yM4PtnoM9fSmxMpKLFuSQ8M5kwDn+Qrsbb4Zau7Znkt1GOmHbt14Aq7B8LpFObzUtq5/giA/9CYUcyDkZqfAXUVj1DVNNY4EiLcJznlTtb9Cv5V7WCo6Zrynw14e0XwzfLfQTGS8AKB5LlACD1AVeK7FPEtsyBhLbY6584UudFqDOmDivOPjnaR3Hhm1u22D7JcAkvnGGUjHHqQo/GuhfxLbKcNc2gJ6fvRzVe61uwvIXhuLqyaJh8yuu8H6ik5ofIfOMdyjJ5Zit1RmBZ/LJZe3XOce3ekW8eNpVgZFV1KNhB8y5z3HsDXsFzbeD7hysuj2wYnG5LeVM+42jFVf7F8GswAsFyf9mf8A+tR7Qn2fmeVfbnjnR7Wd0ZcFXACEH2I6c0ya7bCHe44wSTwSPT8MV6yNJ8JIx26XLIUHOIXOP++nq1BLolrtNpoAGfus8cSf4mj2gezPHkklmBWJJZpM8um5sjHTAq/baJrM8bCLSbuTeB8zRMu3nsTgV62dZvMFbSwtIiDz5krvtHrhQo/CqrX2sSkE6hDACTj7PbqAfxbcc0vaFKmcHpng3xIs8NxBZLHLG4dfMkXgg5HAJr6E/tqMwrI/yFhlgf4T3H4V5dcQS3W5bq9vrhTn5GnZcD1ZVwMfhSwadaopWOKFUJ3bedhP+yCetS6hSpmj8TbKx8UixYajFDLaFwwUeYzK2OAoOc5WuDbwtp0ZwZdXuCnBVIFiH5seB+FdmkMSOwWMKT2wM/8AAqURcAYXK9MY2j6HPP0qfatlezRx8fh+BVxHoO7PKtdXxO/2wgFdpa67qMdrChtQjoiq6oEKpxjqW6cUwIMbtu7JALn+L8O1CjoAp3AcAHleeue9LnZSikWD4j1THyw8dtyoNw9RzzTv7f1ByBhRnrlVwPYnNVmT5GP8A6sM4/LHBppjO8KExjPHUgepx1FLmYcqMe6t726a4uZW0VnkcvsnsHMh/FQQapQ6Vc+YXubPw7cRdShSSJj9CF6/XNdIGYKMjhTjODgeynsajDMWKY+vsOmW7VXtH2JcEc/exWxt2aPwrajy/lybnI9sDYCRWHcx3MZeO48N2YJwqgArtLHAxyc8kV3RLdeCAPvDoBjGAT39qpahbyXEcQhdYnikWVAyZG4f3hnIFVGeuopQ00Obt/BAGWnvV4/55Rf1P+FXG8H2KrIz3FydvOdy/wCFaMl7fKjRslsZ8cKN2GHqvPP4ciqQ164LFJ7WBQ2MkOxI/SvoaUaMoqUVdHkzlVi7NlKLw3pxMoc3XyjI/eAZ/SprXw3pUsOHS4Eg7+aa0bhCjrLGQ0ci7l29MVLaQvcShzlYwR+OK29nS6Iz9rU6syrnwZZuv7i6uIm/2wHH9DWTL4QmWcRrd25B6MyEfnXfsnQAZGaZJGrFSD8obPqBUvD030Gq811ODTQNd0t2NlMYwerW1yY/zGRVe507W5Obm4kbPXzLosf5mvRHZdrevp6Vj3MXzB92FXr7Go+qUyvrMzlYPCV3OpdprZGHblif0qRfCyKB5t2+70SP/E108LTbgIUPHfsee1TMktw4UoN3cD/GqWGprpcTxEznNL0LTmcxTxSSk8bjIQfwxiq2o+G4VuHWwuHB4IjkG78Nw/wro722TTsTSEGYfdjB4z6mm6LCW3XUw+ReQTxk9q0dCny2sQq0073OMvfDt/a4EscByM5WQUlt4fnkHMsSY7KpNdTqsxmmBPTOenFVpJRFEdvDEY9/pWDwlNM1+sTaMGHTY7e/j/e+bs5+7gZrufD8Mcs8AnjjkUE43oGxwa4tm2zgg5Ynt1Jrp7C4l/tSC1tELtGD5m3sdp4rSFOMU7Gcpyk02bzrudicFgThgeCPr/hTvLbkEfXA/wA/rUsqsSQRlQeGzj/P4dqXaqqC6fMwPAzz9AP618me6RhMj5SCQOoAOP6UoVeXfIA67uB/iae8eCAo2EdBncV/oMUoAJJwwA+8evb1x2FBQzaAwJGB1PHp9P60KoxkAAemeh+tPIx2wSfk3Djpxx3p6jD7sHAHzeg/HoPWgCHAQ4bO49Vx14/WlUDnkjjjHOD/AEFTBQccsQ33Wzx9M9SadgnBIPXv/MD/ABpAV+4K8FunXDfU0mwhdoHH8IPGPw/xq0wyS2QT/CwOdvrn+VNKAtwuPYnr/jimBVc8MxYHtgHqPyo8sFRhl2ZyCSQPy/xq0EO4bQRgcDAJH+H40qxrkkkYz8yg9ePU0AVpIA+4MrYKkMhGSR39hxUGl6DpaRh9Qtxd3Bb53dvlIH3cg5BIHHT3rTWIKq8AIT8voPw+vrT0yASPvfxcckD8OKak1sJpPcmg+zWoAtNPsYQOcsuTj2AxUsl9elRsltUQ9CsAP/oRqtsHOcDnvnH4nvzSlCTzsByOPXvx6U+aQuVDjcagzf8AH5IOOQgVMe4wM/nUDxTyD99dzyZxz5zE+vJzgVYCrkqGXp1z0PXk/wCFKsY3EkqMjqeF59BS5mPlRT+yFm5dmU9UJOM55xzzSNp6MP4SwGVYryOwAHatBOgUtznjJywx6DtT0TcVxtJPQk4HA789aLsLIoiwA+VFRUOSVznJA45/pUyWgVfuqf8AaC8jtwKuKg28hQO+f6etSrGoAwoB4Ge/40rjsUfs6jI2YI6gN1/H1pjQYHDDjvg4GPX1rRWJQm3bkAYAHQHrTHTGGPy9t23qM9MdqQzNa2+YAB8ZzjkE8fw+lRrbc4AbaMAnccY/2q1WgJJUx/OcnZ3/ADpCoHIIIXHKjAXjow707isZXkMFHyZyQASflH+7TvIGQSNy5HXGW9m9K0BDtwWIA4xk/wDoPpTEjPQA9ACRyTz0ai4WKf2fcMN1/udAnPXI69aTyyAzqygNwXx156bexq8sWdo2qfTHK9e3rSMGDFskHkb8YJ9sf1p3CxWEBHyuqhRk4PUe5PepNqMSVwcjlgCQeewxx9am8o42bcDJJQ/zz1pzb2ZnaQscEFgvIHpjH60rgVinGGGOc7MncfcnuKjeMljgrgdx9zrx+NXHhHI4UdQnVj9DjpRgMueGwfwHHcUXGUTESSfnGc5JGGx7Doc0eWg5AAIBwo+7+PPBq4IxwV2hTzknr9DStGMH5Tn+7u+b8eeRRcCmUBHo3TfjkfT1pvlrsLBUx6DufX271bKYAOUyBkHPy/h6GlLEA43b8YL/AMX0x3pgUmQ7ht4bGe3A/kR71HJGQqnBER7jqx9j2q40aKwEkedx4jX+I+uex9qaYwoJbd6OwGNn1Xv9aBFUW/LDD7gc4IHyj3H9ajMSMm7J292/i/A/0NWzAMrlMqwyMnGffOOPpS+UCx+UiTHzOBwo91/r9apMRnSWzOrKoAOOAei++PX6Vmtp8u7cYgctjcB1Pp05/wA9810IVRjcPlzkZPzH/dP9Ke0blycZkx0x0Hqw6H6iurD4qdC/KYVaEavxGCtpNHsUoJEB3GMHBX/D8f0q4LmJFjBUwluBv4yfQHofXiruwY+QYB6EHn8D/SkEef4QeeEx09yM8VvDMKsXd6mM8HTl5FbzHJwFzg1CzEMCdqn0zVl7SFgQYwM8FwMfgD/jTFtY4V+SPaoOdpQZPv7fUVu8zdvhMlgVfcqeYDtKo2xjjftzg/T/APVVa4aVMyKomIODjBIHqBWrs/eA5wcdQQQOOmelI8cbRlGXK/xK2R+nb8KiGZST96NypYJPZmbDMsi8HafcYx+dSojoiBZOp3Njv6VPJEN2QzhiMZDHGP61DJaKCTk4znqw3H3x0rf+04r7Jn9Sk92Vbq2tzcBriRnOThBySfSo725cQFIIcRqcfMdg/Xv+VXfs5yCEQMT/AAj+nf8ADmgoO+dnQknr/n0NYyzSbei0NI4GKWr1OYvC0c3+lCVUIyJEA8s/jg0RpZzOgKM0fRnLhgPy/wAK6E2ibmaFfKdh9xDjI+nSqV1pEMpJkjhds8so8sj8Rxn8K6KePpS+LQynhZrbUq4s9vl6emHI5kVcsB3x781b0ePF7ArsYYQzBYlOSflPLHuax7vRbhCGtGkUr90ORkduo7Vv6VFJJqcBaH7oOWLAAnac10PE0rX5lYxVGfY3ZFJldWUg87c/eI6E9PwpqnJyQwI+VgONv1OO1PO8blIG4Mcc4zg8cdTTx/eIIBGNjD5vbjPHevlj2iIBSQuwkZG0AcfQfTrT2Ulgdp3D7yjk47fTJ5p2A2Y1Py9QQcn8+g9OO1PPEZOVznByePf60hkRRUAPyle+DwPXmnbSQMhc9sjg+vFSlACARkNyGI6egAxRtcOAT+96k5ySPf0pjGgAEk5HPGGywP8ASkbOcx/KwAxg8H0ye9PHzJhguxuCMYHvk09geNxUOASrBQACfSgCLavlqWB244H/ANb696cqnopJbGRzkkdyT25pVbcwKjggZBA3e2fQd6eOSE+QDqORtwOgPrQAgQGIYwVZucDAHrzjnp2pSu4gnqBkNgfoMelOQFWOQhKcHjqOvyjNPEZwFycNwAOufr24pAMMeCxQLuP3gGBP59qCqsw3Y8tTkHOAMe3epApwdu3cOcYOz0HPc1MOA7DG0dWYHj2A780wIVX+JjjPy/PyWHsOwpojIABGMk8Z5GfU1YUOuA7bG4Ct1Zjj9KbtOeEXdnlckEj3P5mi4DPLLDIILAHk9CPrT1+TldpCnkkEkcdqeVjBySGQdweFx6U8RKG+dXHTJP8AEB14oARAzAKM46Z/Xk0+Pc5+RQCMDGCF5549TThhiEEfygZMeeefWl2fulY7SRllf+HHYDP+TQAx1CruIKjkBucjtgCnFCFYAKTzhM8HPr+VPYbHU7DnoQDkkD0pWUA7WXKYGFB5Hrn9KAGE4+fKkDPJH3cD070pwdxGQxxzwS30p4yw3DBb1wNuCen1pXK5JGdoJyxHOe2KQEZjGNpBYDqqNgpn1OKRIy3OYyVzgsfkx05FSkbSVOQc/Iqk/Nx3pi7ioUrnAA2Y4XPU0ANRGUdCEGOvX/gIpu0gq3TdgA45b6+lTOOrCQkHIDkdPpQAEGMdW5z/AB8fSgCHBwqn5mHVB0T3FIy4JfHqvmYPr0xj6VYjwG6YUYwo6g/hQm4nb5g3465G3GaYEAj+Xy/L5ySFxyffPajadzZ+9zkj+H2NWDgxOA2FGcjHzH6c0hBG3PB6AA98fxen40DKrKCDhVVD23fM3HanBF+X92cDHboPVjmp9rcKAofAJz0/Ck2ZXOTtx94H5jz/AJ7UgIBGONqqrkEZz8n8+KRkwuORgctn5j6455FWBHtPzIM5PyDlW78n1pdhJyfXk8/J/u0wKhiLAHCAN0X+Hp3HanbAzYKAsByecqPUHFTsAcEYWNsAOwzv5x0/CkUYIBUdwIx976igCp5ahGKjCN6rjJ6HIxx/nrSG3A2IEDSdUToR9OOauEHfnbh/fGR6AimmMFWVQAp59iT1wfWmIpCMKW2jjozAdDnuKCikAAYHYZ6/Q1aC/caQnHGF449z608RdVOAxB5x8v8APigCj5ZJOMFyTn2PYEfjSFMjgyBM8sWxuz/dPb8augK4IVWA9x82evXPIpdoXAXB3dF6gZ9R0FVcRSEYaTGwnA+4B09yKieMKDliT/eJ4/A1pMFOVO1ifmbPQD2NQyINhwWKKTkAHJx2K00xWKTRsuSd208kcZPuR6e9BQgAEFm/h9B+PUfSrkkJyP8AnoxIxzgfQ9uKj8ojKpuAx8zDk/y5FFwsUzGCXAY4/iwPmP8AjSeUnyfOT/d9B+nH51dZFIXI4z8i9vqDjikKBpCgyX6EEfMv19aLisUDEAQGO0Y+b5cn8fX6iomiPG3A/u8YyPbsa0vLXoCAi/xY4J/Lg0xoiAGGAxPyggZH+NO4WM8xFjt3LvJ+YhTgHHcH+dRtGSxO1Si8Zz/X/GtFomDbVPHVj1H09RTcbuc8rwAF5Pv1wc0rgZ4hGWXA3EcnGMe+Pp3FAiVh8pA+YdW4arhjOwqTl25BHQe59KWROCGZto4A4Bb8e9FwsUWjcFeMsMHHXH61Pp0StqES4GeSWJ4Jwe4qVgBzgEngHHT+o+tWNODfboVGCOeScfwnvmncLEIUmR8DDBiDlsA+gJpgAAVkb5CPmOODnqemeelWGCkb2Vs5JyyjJ55wPemnCMPlCFz1Iy2cflWY0MKFU2tgc5Xf29BgelK46EJ82Pu9SR2wP1p2CW2ZwoGQAxJ9yT0FOIUOcEZHUA4UH69+KQxEVckkhlbvnr6/h9KF3nK7DuHQHIBP9acVBUEbmQ8KSMAeg6ZNIF+chmOcEbjjOO/HagB5V8iQqNrd2HH5UbCT5bs2BzlSSTk/ypyYZflHL9eRwfc9sUPjIHIQfNlOn0J70AC7yrFU+boRk4B+venKpO0qrc8hmBGP7oUUkaBiNxIZflJC8D6VIFKydGG48AnLZP8ALigBVBQ5KsGXnO7lgPftzTcbgVKHpjaP4SeTkmnkbQAzMAOdq9wOBk0ikgk+uFI6Kp7/AI0gGooCDJGBypxgc8D61JtXcAAEJODx8zAenpSqWA3BiFJ4yOnYYHpT+VJVmdM8ZHzMw70xjdoQsrLtzyVGC2Se5pFIwUO1h14HGB0yakAc5VVxIBkgdAT0yaeu0AMGDL0zjCpj8OeaAI1Ds4YMQFHzM3GO5x+NPjVVXq53EbTj5gT/ACpw5C5c7jgeYR1z2A+lSbwCZCFGQeDyx7ZoERsSTkD5wMquDjHIGT+fFORAr4TJVSFO7gLgdqkGEIjYgg4Cqp449TSBc/MyKzrk7v4QT7Z5oGNLYG4MeQT5n8XPTGfWlPBw2Udm6dNwA709Btd3TOQQWGMA/QZ6+9LsIReCFYZAyd3P60AM43BAVKgDCY4TrS5P+sDKOMbzg5yegFTfOrANtLAk4GccetIuM9AygjccZxx2oAYWwSuAFJOUwNxPcik2EkKccYwowT/wKn7v3QbaQmAFY5y3NDRk5zGUzk7ecMB0BoAawXzGICs+3njCAfypoBKPgOM5LMAd2f8AZ9qftQKFKlhkZjXsf60u3LKByTuw5AwPr2oGH3MAAKGYEYJ+bjnP8qaq4JV03OAPkU4C89c4qVFVXwN27IycZzx296aFBjO0sI/QH5vwoENzlPMBJwD+8PQc0MAShA2jONzHPmADp7VIy8rkZfBCrzt59R+NNKswznLEZAOQF7cUDGZJwuw4HPl57+uf1ppDpvckEjJZzyAM+lTOuI9yFtoyC7cvnPT3H1pP4huZlX+HHR8/1pARBFyVxhBy+T94H0+vpQ20gF8FFG4IPvDHsO1PfJAU5LjDeVnP5e1Kw3MfnHOQzZwQPT1xQBEBkhxzJgjI+6MAcn0PNLwdyorbeAW5yPp/nvT2GDucqqsRl88SexpPLATDAAY+WM4B4PXPcfrTAj+ZsuCQnQHHXHqKSQNsCkfMclYx0Pv7dqn2lWG1wTgjeMYC4zgj1prBSCAcK/zMdow3b8PwpiIiMyMN7EjJ34OUHb8KaGUk7sAHGeThhz1xUmz5V2xsqrwAB8/A/WgA5XCAEjaoxx+NAyMkABSc8ZC5y3Hce1G04JL/AD9GbjpnODUjKSwG4lj1UHkDFIilm2ITgAbnAOWI7MMUCGHaEI42DI2tjn6en40jZUoxySDgYHKfX2px5RTtVVbIUE/I30Pb+dO8tt4ONz557FR6ZpgQEnOwODn5SQBtz9KYQrAAnCL0yQCT7H+npU6opwFJBAwZFORwe4/z0poQHbgAqfuoxxuz39ulAiADktk7/TbgY9x+NK6IEwCh55PUD6EmpMkyccyYGSx2lQefxoCqSNroQPvODnJ+mPSgCFwQu5jwvGcfMf8AGkJAUMVBJHGGyo9PoakcfxtwDjYCf5NTccktlJWGecbgP60AREMRsVmJ5JbnP/1xUZKlNzqNmMBTkj/61TPGq7kIURjljnIJ6YA7U1xmUlssw6YIBP8ALPFMCPa2RnIkPA55x/Wom2BW+7hcliOQT34xxUrLhcgAFjnGOAe3Hagr91VDE9SQ3OB6Y4P0oEQkfKG7j7vzcj6etS6a2y8TaWVjncwwOxwCKYyjDOMgZHy98+4/wqaw4u4m3AuSeSDxwe/X86AZAUUTllQhi3zAAEk+/wBKVVTaVC5yCcZI4+tPkRSzxkfIeSqjAHrk/lTAgIKkqxUgZIwqnHt14qAG4DRhVZd68gYIXNOYbQCo47sQf0HqacAgxKCSNvLMvGM9h6k0915IYH5zweSSfYfSgBix7XKOWJJ+U9SD3x6AU6IZQbDlh1UcZ54yaRUDfLsO4DhQTkj3PbNPdnbDEfd4ZQcY9ee+KBiAAgHcpjPXso9+evpRtK8AHI5XfjGfYe3NPCLxjcyjB9Ap7AcU9eONx35JDkDqeuKAGYAUH5lPVi2CzAe3bPapAuJGAHB+XHUlu5J7DrQGCJ5hXBBxtyNzDtz+vNLwnU5QnGFA5J5JJHb/AAoAPL+dV28ckbcgAD1OetL5Pyq3yq46E9Ce/H+NOCqYwrkbQOn8PsDUifOQ2V3g7QcZz0Jx/wDqoAYuAcpuG/kn+I9hTmUIRGwIGNvy9Tin8H5wpVWxk9yO2BSbVULEMgYxjv8A40gGgll/1eSpBCKCAc+p/WlLK2QuWAwp3DCr3z+lSBQwSPJyScIuRwP5+9OO5QDndIq8gZ2gnrTATdtO8uPnywYnb7ADP0p7Fc7SQvIXI6soHPXpSox3sRKCN3zFhgKQPxpWLKvzO2CMrITySew4oAapVF3YxvBLIOvPr+VJu4AYDaTjaSML35qVQzEguYsEDORl/Xt/Omhwy7VGcjLR8d/yoGKMsvzffC8yNjAzSqQcshYAnn5QS2OuM07LN12yLyVJxxgd80qq5zu5kX5hISMA/T1oEIFCxbnTbGw5T+LPbvxSiIeaN/zSZyNoG1eO9PRNrFuFOcElQd2OuKRdyR48vETAnZtBbJ9f50DEJXA5LMANx2kADPUf0zTCU8tyHwhDAyMTnPpUzKS67hgbgEwvU44zimktljj99t9+BnnjtQAmzYCSdhyOe7fWm4GRggHBYxBgSfTk/wCfapFw8jlEZucMWyNvFChPLBVv4SPMbnr65/z0oGGzK7SpkUEDav8AyzpCBuCHh8Z8wAbcHsKcQqynJCAsAMsMOcH/AD+FN8tSufLUZGRFwcc9eRQIQAYcgHBbaMgc8c4HenFQoB2seAwj4LD0qWQhWQOGbc3BBGFx/nFMiXAxkedtz5vGBn+X50AMkRRLlkDOQVU4+X6fzppGGcMuJM5Ixkceh/CpvlV2KHYoxvzgEjHQfjTdu6PGMR4OU7/WgZGicMoYqmCoYZ3Z9OvFIwAjVn2qCww2fv5454xUw+V1Z8Hn5AFzx2BpFBViVT9+w+6M4OKAGMHJAYZcrjZztOO/86Ccu2MM5IJXOdv0NOBCqwQh2xufPUDvinb08sjeXQZO9iQR7cfSgCJgP4GLEcNITgjHOCKaQcs3yRRn5geqyfpnpT43AACuVHaTd976g0rA/LvJJOT5QYf57UARMCRkLlgCBHkcfl1FMf5lOwEkk/NxxnoCPWpcHeATufvhgfL96UgbQqybiqg78A5we/SmBEU3NgKfLBDEH056UbSX3MrY6DI+bPfOev8A9anE/Kysm2MZAUAcnrkU7qPM4PHykAZQfT/HrQBAcgZGAxHBCkqfTjtzTo1wNkeQTy3Un3wR/WpcNgjcFYjl1AZRgf4UhRXUqg2wqc4I4Pup/pQIiwxBPmMFTrhSWz9D1pgAGWY4Dfd64b3PoelTbS6g4+UZwNuGGPx5/GmqG8wfxysMDC/qR260XCxCylCqgr5rZJxu4z1A7elIQSpQE7UHLAYIP0Gc8U9BjCIBg4L7h8h9gaApyQgOyI53AYbjn8aYEAG2Pedoi4AyOMD1+lDKAdvPmEcDJzj2NSsNzEk5bkKVX+Y9KbhlyoAJk7fw/wD1iaBELJk/uzjaOWHX8RjmotwKKAR5Q5VSTgnt24/SrjrvcJtKhcfMcg49R6+lMOPmYBQgHUA/N7EUAVn3BgcsXI4zww/Hv9KiEQxtYL6t0x+XUVaaFgFLA+Y33dwO0+49OKjZN2EUMWA+YnII/HuBQBAcYVyoAB+Xkfoam0uTGoIScuSeDgMBg/nTHOSzDAjUkcAkH/A1Pp+Fu4WYBSxJGcn+E5IPpQBUKh1bZj755ZcLkf8A1qUDcwcDKY2jcpHy+wp0sg37lVQOm9gRgZ4496RsLJudmBfnLHBY46Ae1SIViEd/mxv74OS3oPpQoUsVb5WPYN8xHr+NJGvyhUyDjAORuIqVN3JdWV8ZMatyc9BQAmAQo/5aDGUVsDPoT7UpCbgAwZOhwSFA+nfNOUD+GPOPlwrcA+p/lTQm85OCueBuAVR6fnQMUDc3DNknIYnjPoB7U/B2uA7BlBG4nqB1PHrTgjO5QSOWGMOenPXA/SkIUAOFKgEjd94kA9vxoAULtXzAGycbwvLN6D8qQx5IRgWQ/LsU8DuSTUiqygs+VJOSMZJJ6fSlkLIwhIypB42jIA65pANQhm3SFWIAYZ4XHb60/IZtwHKfIXK4Hzc/5NLCvmHMi8jDdMKP7opwCtgKFaUHBcjCg98UAMXIzKI/vHJbBJ444FARlRflAU/dO35iTUoKSSMyMPmyGdgeAPYc0uRGNw2lNu7c3Bz2x+FMBrxqFMbKVJ+VeTuPrT1DuwJ3LsOQinqO2T6UbSIysj7ONquTksT6YqQRMkRBA25xuDct+VAAobkbl+7hkBIAJ68+vNP2neWVN4ONpJwFpqABt3LSY3eWrflmpVGcop8wdCgPA98HHNAEeWUCMZU4/wBYzf5/IUuNzMEHltkKRxlsU/yywIJ8xScggjCY5xShWZzlvMlTLB2TKnPf+dAxgOeVjYJtyyHk5J/mfenIjEkFC6kgAKo+X6mlIBY+XkkHBLDHH+NSMzeWH2t5RXcVxz9MUARsgHDDLjJVhjavHApyg5YRfK+0b2OMN9Bj8aUbVjw7II8cBfX1OffNSOGYqrg7t3yBU7DntQBEV+UNDuEOTvYjDdOo/Wmyou1Q67VwAhGS2fxqeXaR8rI0wUnachQD9KYmSWwgzu+ftt4GMf40AIQfMRTvSQNhFyfm47/rR0j27GZiB+7H+f8AOKkj2kZTDxEnc5cgL2xnHSgR8lWYheBuzgt9PbigBj7CRnbIgIHXIj9+lOBdSBHL+8II80kdPc8k0+MDk7CmTnZu5b8KjUrhS2VTbnyhg7ff39qADcFUqMJg8k/8tD+maRXfyjtU+X2i2gkj/PrTtqL5ZdWZCRgAcCnBd2FwGnwTuCjHXp/9egCPCpEryKdoK7QEHyH6UMHZhk75OQrEBgD/ACqQABmXb85++SvGM84/Wo9gKlVQhM7W3Kcn3H/66QwRR5sqrGd4I35HQdOtMCKyYCsYwdp3ZBX0I9vanBUaFSSTF/eAw2e1PkO0qScJkFSMkk46nt+PemAjpvG9v9WQCrjKnPqTxSbRgM5XaR8u0Ha3oTmlIcj7480ggr2btjP9BQwaMno0pA3IvY9+v+RQAzy9pIfAfGNjkkEcfSkBAkwhVpPvMCSCM8cfSpmGGYI5ZQecHDD86ZyhCnByv+tLduvJoAj2bwQsg2hR+9H3voRj/wDXRtJchdqqDwuQQx6ZqQYBAyF5BJXGHOP88YoK5AQgBcECDOd3uOOO9AEJKgAhMAnCocZyMnimshLrIMtIf+WnGU+o/OpQCzAhtxGMKvWPP8uKciEEEOZJOhkUZGKYEGdpOVG5jlsj5WHfn8PWjagVgRhU+XbnGQRn5fWp1QshVGTBwZMjKsP5frUW1JMgL+6jI2qR8ykdO9AiJ4wApMb46gADIHfI44FDKUyzvulbK52jHtkCngMq7yoIz8mFCke+PT2xSMMZYhRIy/eABX9P8/lQMjxy0ZGOm4Fcq3HIHPT8qY8aSEqy5x1U9c+3r0qV1ZVa3RQAcs2cMp6ZAOeKSQZUooLIpyRj5lPse5696BWIJGDZlxuIHJAG/wDz+FIVZQobLBuDxlST2x2J9alJGfNU7lXoVXp+HTimqPLw2AHkPBC5U9+fTNAEZiTAj2qATk/4g+1RkLu3sSFGOdp3Z9/Wp/KxhAo6bmBU8D/Z+maUhXGB0iHJCkOPY/rTEVWQrls4LLgHkqff2/Wmup8uNACeQ+z9eOf6d6sBWEfnLs2gHDEHafTP0qKQFUyQvmNyEJ6+uO34UDIQm+TBdm2ZVmyQQe/FTabIftaSMRs5wQThhg4ppTIUKwY+meR7e4/CpbEE6hDiQDryOg4PUUCKsiN5zlmwSchnzjPoBRGuPlDmMr0djliO5p7kqr4f5lb5XcAc9yKaGXYshZgo+8GU5I7D25qRAV4wVIwPmwQWIzwKUKwwUCjPUKASSemT2p2fJ3vx0B3EEkt0A+lN2hW2fKivwFAOT65NADlXHybV8sgYUYwB3yacibmwOo5XIGF9KZsXiFlVB1CgHOB0zTsn+NE85PmCgcZ7Z/CgYHJAaJgQPkLMvBHenK7DEiqApGS5U8qKecs+4sJnRQoU/dHHP5UfxGRApXHzMD8qAd6QDV4G5gqow3EnIYk1KwJQRGMqp4VQCCQPU+n1p0SEMGJYrncXZhx6AZpGRmUxneGP8Z79yRTAQsCwV0AIbcI0bqPepyZB8wiUso2rGo/nTI1eVTtUxqTgE9WUe9TZCxB+UiBJYlclvoD70gGYK/dXcT8u0NnGOp9OtSptDAlXdWyRlhhcVHgKqopVYwOUVecnp/OpSjKgRyTGRs2hSTmmAi7fMcgbjncHYjG45p+A2UDnzMY81lGRz2H/AOulJyywSglycqqgjOOn/wCqkAy2ybYXY52KCAO+KAEJDErGCo43HkkinxgKqlAyx8koQMsewx/+qgAyMPMVHnRfu7SoXPb0pMbNzoilzwTuGFxx+dAybZhGBUGIj5VVMY+tNwB+7YbcnCKBg496er4H8BJYnezbRgfrTVORt3EhgTv34I9/60AGfmQMv75QWwP/ANftRgtIfICyMDhySRtH+NPUZjKE7VIH7zcCSfw7+1ODeZwmU5b5T1fHBJPpmgBjKEYFdrKzZcg/d+lKFURhQY/LOdznIOf/AK9PCqERk+UKSSmQSaQRqecMI8cxdTz+HGc0gEZN4Ks0ccQA2/N1+v4UKMhTIeQSdiNgY7f596eQA26Ul1IGxcjKn3p7HypdjlWkJ+U43H65/LpTAhVQ67nGFGf3fQUMp3ZJJjOP3ajPX1z07VIA+/5gwuCcLxn/APX/ACpMEcRhfOwN4I+96nH6dqQxqqxJEgMgJ+VlGQP8O3tTsN5mN5acrjdgEEemfw60fIWkMfzR9HBXoMdqbGitGIxjyyCNzZHfp6dxxTAeqgs4iVgwcGQgDHPf+XekVRtAiG62GVJKc/Q0OOMSSgKPmD5I+uc9z7U8Zd18z92yscc4B/woEQCMNCGcFYVHytzkEH1/+vTnDLsZ9qgH931XP1x2+tSEZk3v5e8rnyz6f4UuGUFl+Y4yYw+dh7k96BkLK7YDKDIwwE5GRmgKyOQqDzCN7JnkdBwf/wBdS7UU4Q7xnGd2Cvegxdt4xt3CXPX8u386AIeQwCAyjJUtkgoPYfpzSKm0hdwIxjzAfujrj2HH1qaTAOxc5I3NLnGQMDJ747U0qd+OgB3SZACuD6eh6UAMMmGDM4VeP3gIO7nof8DSMygEAGNO6kgBvb8amAbODv2g7WjZB164Ge9AJMQcYaLbkRsB8tAESoSTkZB4EW7I4PUUpwD5h3FRgqBjKn8ql3uVR5FLA/ccg857nnihlkRl8wlLg5wQgwfrQBWZSv3gxkf5dw568jPf1oeP58RDD53MGU8jHr7U6NT5rKq/vBgupyRg+h/+tTdqD9yioyDO7qcc/wD6+1ACNECDGiHYv3s/zH+GaZJkIHZSUT7hA+Yf4808KBuHmEhWx5jZBBAzTkw4LbRhSMMO/sf6mmIjJGd8gIdshXUdQf5H8KaVYEdVkOCwI+UgdMehpz43h90SuflAUnax7H+lKpRVKBVJcktGeoAHJFAEKoMtHGnHVgM8jPbvimrhvl48pcDJX51NTMiiPy+p4UsW5/wOPakYBwmH+XPEinB465z/AIUDIDswZCcR8BXCkZ9j6/8A16HzEedvmMMfMPlOKflGkLMAhACqAcKw7D19D2pqHBJBVWJztZjjOeooERuvVMByeiNn8QuKY8TPIFySq8/MSGHoQO9TEqke1M8csm7LKCevH196bIU2bP8AWjOCQ2CM/hz9aYEYActIQdqjaWQnHH973qOTad0mYwc/LlvlPHH41O2MAIwJXH7wE5B9TTXIY7QQqbc7iwKkd8+lAiq8QjUuwL5G3aXwffnvU9i+L2MKxPLEsDyOD2/z0ppAkkbcpKqRgMec9sH8uKlsGKXaOd5JJxyAw4PB9aAIY4Ipbm5Mi7iFAHPTkVNBEhU5BOZW6kmiipYiKJFS2eRQd43YJOcUyCFGsnlYEyAA7txz1oooGLcqI7VXTIZnCk56j0o6SxkZBYEn3NFFNCexckhj89k2jYqcDtz1qaKCORisiBl3BcH0xRRSAijjVpQGGQjttyemM4qRY1a4XcM4UkDsOvaiihDFjRSZ2IyQNo56DHSnwwRtczllyQgxyeKKKEBLa28TNLlf+WmOp/u0llCkqqZAW2vtA3HAGPSiikBFbk+UTk9WHX0PFWREgAcAhtq4IJyMsQcfhRRTQC+Ui7lVdo344ODjnvT3jRAAqgZ5OO5yKKKBjokVQuAP4j+NMt1VgykfLtzgcdTg/pRRQgLa28UnysvyjIABI74/lUbRq0u8j5lLYOfQcUUUCQ2OJHHnMoMgGc++4ipoIkZpWZckqOv4/wCFFFACKiqsigDHmEc8nGB3oto1a2DEHO8r1PTB/wAB+VFFA2Ms41NiWI+YSMAc9s0+ZAtnG67gz7ckMeaKKBi3fyTKFJAJ59+R19ai6vk8kgn8c0UUCHxgNMVYAr8owR6jn+VLsCmUdQuCAxz6+v0FFFIY9okfZI67pMA7jzycGkZFx520eaq7g3vuNFFMBIlXyy+BuYAE+vFCqN8qYwpiLkDgZzRRTERRkm7igJJi8rO3PcUSQRtC8ZX5UQMvPQ+uaKKkYs8SNIhI6EAc9qleKP7aMKAB2HAPTqO9FFUDGmGNL0bQRvB3YJ5xSQxqb2eMg7BHv254yetFFIXUrIivbzAg4ViBg4x37U+CNWtdxHLjLY4BOQOlFFMB0yhI4iuRuyTz1PWq0ij7ZHEMiMgsQD1PrRRSAEUMGVhlUwVU9AR6CiIfOM5JDYyTk/n170UUwCZQN0oH7zZ97v1NSFFExQKoU9eOTx60UUAUxGhulgKgwlGbb2zzSLzPIpAKoybQRkLx2ooph1Gx/NEsh+/6/TIpcAReb/y05+Y8npRRS6gyAEtArtyzBcn1zU3kx/aY4di+UznK44/D0oooewEQhjKyJtwEUbccEfjTrZFS6DKoDKcAgex/woooQj//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30929=[""].join("\n");
var outline_f30_13_30929=null;
var title_f30_13_30930="Posterior dissection vulvectomy";
var content_f30_13_30930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior dissection for vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30930=[""].join("\n");
var outline_f30_13_30930=null;
var title_f30_13_30931="Naftifine: Patient drug information";
var content_f30_13_30931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Naftifine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8643?source=see_link\">",
"     see \"Naftifine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naftin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to naftifine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10887 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30931=[""].join("\n");
var outline_f30_13_30931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199234\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013438\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013437\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013442\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013443\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013445\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013440\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013441\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013446\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013447\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8643?source=related_link\">",
"      Naftifine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30932="Timolol (ophthalmic): Patient drug information";
var content_f30_13_30932=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Timolol (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=see_link\">",
"     see \"Timolol (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=see_link\">",
"     see \"Timolol (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betimol&reg;;",
"     </li>",
"     <li>",
"      Istalol&reg;;",
"     </li>",
"     <li>",
"      Timolol GFS;",
"     </li>",
"     <li>",
"      Timoptic-XE&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg; in OcuDose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timop&reg;;",
"     </li>",
"     <li>",
"      Dom-Timolol;",
"     </li>",
"     <li>",
"      Mylan-Timolol;",
"     </li>",
"     <li>",
"      Novo-Timol;",
"     </li>",
"     <li>",
"      PMS-Timolol;",
"     </li>",
"     <li>",
"      Sandoz-Timolol;",
"     </li>",
"     <li>",
"      Tim-AK;",
"     </li>",
"     <li>",
"      Timolol Maleate-EX;",
"     </li>",
"     <li>",
"      Timoptic-XE&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to timolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705323",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All eye products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Turn container upside down and shake once before each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696183",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use other eye drugs 10 minutes before the gel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12321 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30932=[""].join("\n");
var outline_f30_13_30932=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600186\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600187\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024712\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024711\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024716\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024717\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024719\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024714\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024715\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024720\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024721\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=related_link\">",
"      Timolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=related_link\">",
"      Timolol (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=related_link\">",
"      Timolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=related_link\">",
"      Timolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=related_link\">",
"      Timolol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30933="Lopinavir and ritonavir: Patient drug information";
var content_f30_13_30933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lopinavir and ritonavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     see \"Lopinavir and ritonavir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/16/27914?source=see_link\">",
"     see \"Lopinavir and ritonavir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kaletra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lopinavir, ritonavir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hemophilia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an irritated pancreas, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid with food; tablets may be taken with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699430",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator or at room temperature. If stored at room temperature, throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect solution from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10815 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30933=[""].join("\n");
var outline_f30_13_30933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189776\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189777\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027714\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027716\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027715\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027720\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027721\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027723\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027718\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027719\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027724\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027725\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=related_link\">",
"      Lopinavir and ritonavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/16/27914?source=related_link\">",
"      Lopinavir and ritonavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30934="Midshaft humeral fractures in children";
var content_f30_13_30934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Midshaft humeral fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30934/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30934/contributors\">",
"     Leticia Manning Ryan, MD, MPH, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30934/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30934/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30934/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30934/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/13/30934/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the humeral shaft are uncommon, representing less than 10 percent of all fractures in children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/1\">",
"     1",
"    </a>",
"    ]. One of the most important features of humeral fractures in children is their ability to remodel and heal with minimal to no deformity despite displacement and angulation. The majority of these fractures can be treated by immobilization alone.",
"   </p>",
"   <p>",
"    This review addresses midshaft fractures of the humerus in children. Fractures of the proximal and distal humerus, including supracondylar fractures, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"     \"Evaluation and management of supracondylar fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=see_link\">",
"     \"Epicondylar and transphyseal elbow fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19175?source=see_link\">",
"     \"Evaluation and management of condylar elbow fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24855?source=see_link\">",
"     \"Proximal humeral fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thick periosteal sleeve is present along the humeral shaft that limits fracture displacement and promotes healing after fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Fracture patterns in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following a displaced midshaft humeral fracture, the radial nerve is at potential risk for injury. Although nerve injuries may rarely be associated with long-term sequelae, the majority are neurapraxias, such as temporary loss of nerve function (especially motor function) without anatomical nerve disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humerus is second only to the clavicle as the most commonly fractured bone associated with birth trauma. Neonatal humeral fractures result from rotation or hyperextension of the upper extremity during passage through the birth canal [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ]. A complete, transverse midshaft fracture at the medial third of the humerus is the typical fracture type and site (",
"    <a class=\"graphic graphic_figure graphicRef50851 \" href=\"UTD.htm?18/39/19056\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the midshaft humerus may occur after a fall on an outstretched hand (FOOSH) or from a direct blow to the upper arm [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Humeral shaft fractures also occur in relatively high energy trauma, such as in a motor vehicle collisions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathologic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A midshaft humeral fracture which occurs with a history of minimal trauma may suggest a pathologic fracture. The humerus is a common location of bone cysts and other benign lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mechanism inconsistent with the injury or a fracture in an otherwise healthy child under three years of age with normal bone by radiograph should raise concern for child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ]. Two types of humeral shaft injury may result from abusive injury (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H17#H17\">",
"     \"Orthopedic aspects of child abuse\", section on 'Humeral fractures'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transverse fracture caused by a direct strike",
"     </li>",
"     <li>",
"      Oblique fracture caused by traction with humeral rotation or twisting (",
"      <a class=\"graphic graphic_figure graphicRef74375 \" href=\"UTD.htm?4/0/4096\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Midshaft humeral fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with a midshaft humeral fracture usually has mid-arm pain and swelling. Most fractures do not have a visible deformity and are minimally displaced radiographically [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular injury is rare. However, midshaft humeral fractures are associated with radial nerve injury, either as a result of the primary injury or as a complication of orthopedic manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Injury to the radial nerve will cause numbness to the dorsum of the hand between the first and second metacarpal and motor deficit characterized by diminished thumb and wrist extension and forearm supination [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neonatal fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to arm swelling or deformity, the neonate with a midshaft humeral fracture may present with irritability when held and refusal to move the upper extremity (\"pseudoparalysis\") [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Associated findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;After major trauma, midshaft humeral fractures may be associated with life-threatening injuries of the neck, head, and thorax. If present, these injuries should take priority during stabilization of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine radiographs of the humerus (anterior-posterior and lateral radiographic views) are generally sufficient to diagnose a midshaft humeral fracture. As in every fracture in orthopedics, the joint above and the joint below the fracture should also be seen on radiographs. Dedicated shoulder and elbow series should be obtained if these joints are not adequately visualized on the humeral radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ]. A prominent vascular groove in the distal humerus is a normal finding that should not be confused with a fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Midshaft fractures are classified in a descriptive manner by their anatomic location, fracture pattern, displacement, and angulation (",
"    <a class=\"graphic graphic_figure graphicRef82018 \" href=\"UTD.htm?30/59/31667\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Fracture description in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with midshaft humeral fractures, initial therapy consists of pain management, immobilization, and radiographic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral analgesia (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose: 10 mg) is most appropriate for initial pain control in patients with moderate to severe pain and should be given prior to radiographic evaluation. Oral analgesia (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    may suffice for patients who have suffered a nondisplaced midshaft humeral fracture. Patients for whom procedural sedation or operative care is anticipated should not receive oral medications. In most circumstances, pain relief will result in an improved ability to assess and obtain necessary radiographs in the apprehensive child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immobilization enhances patient comfort and prevents further fracture displacement. The arm may be placed in a sling and swathe or shoulder immobilizer for comfort. Neurovascular status should be checked before and after the patient is placed in a sling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Orthopedic consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate orthopedic consultation should be obtained in any of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open fracture",
"     </li>",
"     <li>",
"      Fracture with neurovascular compromise (radial nerve injury)",
"     </li>",
"     <li>",
"      Completely displaced fracture",
"     </li>",
"     <li>",
"      Midshaft fracture with clinical deformity or angulation more than 20 degrees in children and 10 degrees in adolescents",
"     </li>",
"     <li>",
"      Fracture with evidence of compartment syndrome (rare in midshaft humeral fractures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a humeral fracture in a child with no plausible mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Child abuse'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the medical care team should ensure that fundoscopic examination to assess for retinal hemorrhages and skeletal survey occurs once the patient's clinical status is stabilized. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants, a sling and swathe (with the arm wrapped to the torso by an Ace&reg; wrap) is sufficient immobilization for a midshaft humeral fracture regardless of fracture displacement (",
"    <a class=\"graphic graphic_figure graphicRef78370 \" href=\"UTD.htm?26/7/26736\">",
"     figure 4",
"    </a>",
"    ). Because of the rapid, predictable healing in this fracture, immobilization may be limited to four weeks (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80675 \" href=\"UTD.htm?12/23/12660\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thick periosteal sleeve of the humeral shaft often limits fracture displacement and promotes rapid healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Immobilization alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children or adolescents with incomplete fractures, a sling and swathe (",
"    <a class=\"graphic graphic_figure graphicRef78370 \" href=\"UTD.htm?26/7/26736\">",
"     figure 4",
"    </a>",
"    ), collar and cuff sling (",
"    <a class=\"graphic graphic_figure graphicRef68874 \" href=\"UTD.htm?33/29/34270\">",
"     figure 5",
"    </a>",
"    ), or shoulder immobilizer may be used for immobilization. For complete or moderately displaced fractures, application of a sugar tong splint to the upper arm and a sling to support the forearm is recommended (",
"    <a class=\"graphic graphic_figure graphicRef69310 \" href=\"UTD.htm?5/12/5315\">",
"     figure 6",
"    </a>",
"    ). A hanging long arm cast is an alternative for older children and adolescents (",
"    <a class=\"graphic graphic_figure graphicRef67819 \" href=\"UTD.htm?20/44/21185\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The hanging cast uses gravity to decrease fracture deformity by fatiguing the muscles and often improves patient comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Closed reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of clinical deformity may be considered more important than radiographic alignment in evaluating post-reduction results [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After reduction, the child is placed in a coaptation splint (a padded, U-shaped splint placed around the medial and lateral arm and up over the shoulder) for approximately two weeks (",
"    <a class=\"graphic graphic_figure graphicRef63053 \" href=\"UTD.htm?22/14/22754\">",
"     figure 8",
"    </a>",
"    ). If the fracture is minimally displaced when reassessed, the child is subsequently placed in a functional clamshell brace (",
"    <a class=\"graphic graphic_picture graphicRef70631 graphicRef74136 \" href=\"UTD.htm?25/55/26486\">",
"     picture 1A-B",
"    </a>",
"    ) until adequate callus formation is seen (approximately four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/9\">",
"     9",
"    </a>",
"    ]. For fractures that have acceptable angulation but have some shortening, the child can be treated in a hanging arm cast until adequate healing is seen (",
"    <a class=\"graphic graphic_figure graphicRef67819 \" href=\"UTD.htm?20/44/21185\">",
"     figure 7",
"    </a>",
"    ). Shoulder range of motion exercises are typically started four weeks after the original date of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Surgical repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative treatment of pediatric humeral shaft fractures is indicated for open fractures or, less commonly, closed fractures when acceptable displacement or angulation cannot be managed with closed means [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3,4,10\">",
"     3,4,10",
"    </a>",
"    ]. Use of external fixation techniques in cases with severe soft tissue or bone loss has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have received immobilization alone or closed reduction followed by immobilization should follow up with an orthopedic surgeon with pediatric expertise within 7 to 10 days.",
"   </p>",
"   <p>",
"    Children who have received operative care (closed reduction with percutaneous pinning or open reduction with internal fixation or fragment removal) should be admitted for 24 to 48 hour observation of neurovascular status and soft tissue compartments. Once discharged, these patients are followed closely and may require weekly orthopedic evaluation with radiographs to determine the optimal timing for subsequent hardware removal.",
"   </p>",
"   <p>",
"    Most radial nerve deficits associated with midshaft humeral fractures are neurapraxic injuries that resolve with observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial nerve palsy and nonunion are the most common complications of humeral shaft fractures in adults but are rarely seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete nerve injury is exceedingly rare in closed humeral fractures in children. A radial nerve palsy associated with a closed humeral shaft fracture occurs about 4 percent of the time and should be treated conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/12\">",
"     12",
"    </a>",
"    ]. Wrist splints and physical therapy should be employed to maintain a full range of motion and prevent wrist contractures. Impaired nerve function usually recovers spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/13\">",
"     13",
"    </a>",
"    ]. If there is no evidence of recovery after three months, further evaluation of nerve function should occur with electromyogram and nerve conduction velocity studies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"     3",
"    </a>",
"    ]. The prognosis for recovery is excellent, and nearly all cases of radial nerve palsy fully resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonunion of the humeral shaft is unusual in children given the capacity of the bone to remodel [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/14\">",
"     14",
"    </a>",
"    ]. Ultrasound bone stimulation can be used to successfully treat delayed union when it occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of midshaft humeral fractures are uncommon in the pediatric population. The prognosis for healing and remodeling is excellent, especially in young patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30934/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Midshaft humeral fractures are uncommon childhood injuries that typically occur from a fall on an outstretched hand or a direct blow to the upper arm. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pertinent anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A mechanism inconsistent with the presence of a midshaft humeral fracture in an otherwise healthy child with normal bone by radiograph should raise concern for child abuse, especially in a child under three years of age. Abusive injury may cause transverse or oblique fractures (",
"      <a class=\"graphic graphic_figure graphicRef82018 \" href=\"UTD.htm?30/59/31667\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathologic fracture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Child abuse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Child protection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H17#H17\">",
"       \"Orthopedic aspects of child abuse\", section on 'Humeral fractures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child with a midshaft humeral fracture usually has mid-arm pain and swelling. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detailed neurovascular assessment is important to identify radial nerve deficit manifested by numbness to the dorsum of the hand between the first and second metacarpal, and motor deficit characterized by diminished thumb and wrist extension and decreased forearm supination. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine radiographs of the humerus (anterior-posterior and lateral radiographic views) are generally sufficient to diagnose a midshaft humeral fracture. Midshaft fractures are classified in a descriptive manner by their anatomic location, fracture pattern, displacement, and angulation (",
"      <a class=\"graphic graphic_figure graphicRef82018 \" href=\"UTD.htm?30/59/31667\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80675 \" href=\"UTD.htm?12/23/12660\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61934 \" href=\"UTD.htm?37/24/38273\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Definitive care",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of these fractures are treated with immobilization alone and do not require surgical intervention. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Infants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Immobilization alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The emergency clinician should obtain prompt orthopedic consultation in selected circumstances. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Orthopedic consultation'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The prognosis for full recovery without functional limitation after a midshaft humeral fracture is excellent, especially in infants and young children. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/1\">",
"      Cheng JC, Shen WY. Limb fracture pattern in different pediatric age groups: a study of 3,350 children. J Orthop Trauma 1993; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, et al.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1537.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/3\">",
"      Shrader MW. Proximal humerus and humeral shaft fractures in children. Hand Clin 2007; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/4\">",
"      Caviglia H, Garrido CP, Palazzi FF, Meana NV. Pediatric fractures of the humerus. Clin Orthop Relat Res 2005; :49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/5\">",
"      Carson S, Woolridge DP, Colletti J, Kilgore K. Pediatric upper extremity injuries. Pediatr Clin North Am 2006; 53:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/6\">",
"      Shaw BA, Murphy KM, Shaw A, et al. Humerus shaft fractures in young children: accident or abuse? J Pediatr Orthop 1997; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/7\">",
"      Benjamin, HJ, Hang, BT. Common acute upper extremity injuries in sports. Clin Pediatr Emerg Med 2007; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/8\">",
"      Landin LA. Epidemiology of children's fractures. J Pediatr Orthop B 1997; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/9\">",
"      Sarmiento A, Horowitch A, Aboulafia A, Vangsness CT Jr. Functional bracing for comminuted extra-articular fractures of the distal third of the humerus. J Bone Joint Surg Br 1990; 72:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/10\">",
"      Huber RI, Keller HW, Huber PM, Rehm KE. Flexible intramedullary nailing as fracture treatment in children. J Pediatr Orthop 1996; 16:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/11\">",
"      Asche G. [Use of external fixation in pediatric fractures]. Zentralbl Chir 1986; 111:391.",
"     </a>",
"    </li>",
"    <li>",
"     Sarwark J, King E, Luhmann S. Proximal humerus, scapula and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/13\">",
"      Shah JJ, Bhatti NA. Radial nerve paralysis associated with fractures of the humerus. A review of 62 cases. Clin Orthop Relat Res 1983; :171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30934/abstract/14\">",
"      Lewallen RP, Peterson HA. Nonunion of long bone fractures in children: a review of 30 cases. J Pediatr Orthop 1985; 5:135.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6542 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-5796C5686A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30934=[""].join("\n");
var outline_f30_13_30934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathologic fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Midshaft humeral fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neonatal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Associated findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Orthopedic consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Immobilization alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Closed reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Surgical repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Definitive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6542|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/23/12660\" title=\"diagnostic image 1\">",
"      Infant humeral fracture healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/24/38273\" title=\"diagnostic image 2\">",
"      Child humeral fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6542|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/39/19056\" title=\"figure 1\">",
"      Mechanism for neonatal humeral fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/0/4096\" title=\"figure 2\">",
"      Mechanism for humeral fracture from abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/59/31667\" title=\"figure 3\">",
"      Classification of humeral shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/7/26736\" title=\"figure 4\">",
"      Sling and swathe splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34270\" title=\"figure 5\">",
"      Collar and cuff sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/12/5315\" title=\"figure 6\">",
"      Proximal sugar tong splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/44/21185\" title=\"figure 7\">",
"      Hanging arm cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/14/22754\" title=\"figure 8\">",
"      Sling and swathe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6542|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/25/18832\" title=\"picture 1A\">",
"      Functional upper arm brace",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/28/10690\" title=\"picture 1B\">",
"      Applying upper arm brace",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=related_link\">",
"      Epicondylar and transphyseal elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19175?source=related_link\">",
"      Evaluation and management of condylar elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=related_link\">",
"      Evaluation and management of supracondylar fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24855?source=related_link\">",
"      Proximal humeral fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30935="Clinical manifestations and diagnosis of chronic pancreatitis in adults";
var content_f30_13_30935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30935/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30935/contributors\">",
"     Steven D Freedman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30935/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30935/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/13/30935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis is a syndrome involving progressive inflammatory changes in the pancreas that result in permanent structural damage, which can lead to impairment of exocrine and endocrine function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/1\">",
"     1",
"    </a>",
"    ]. This disorder contrasts with acute pancreatitis, which is an acute inflammatory response to pancreatic injury and is usually nonprogressive, although the two conditions may overlap. Recurrent episodes of acute pancreatitis may lead to chronic pancreatitis over time.",
"   </p>",
"   <p>",
"    Chronic and acute pancreatitis can be distinguished by several features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pancreatitis may be asymptomatic over long periods of time, can present with a fibrotic mass, or there may be symptoms of pancreatic insufficiency without pain. Acute pancreatitis is almost always painful.",
"     </li>",
"     <li>",
"      The serum amylase and lipase concentrations tend to be normal in patients with chronic pancreatitis, but are almost always elevated with acute disease.",
"     </li>",
"     <li>",
"      Morphologically, chronic pancreatitis is a patchy focal disease characterized by a mononuclear infiltrate and fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef76728 \" href=\"UTD.htm?36/21/37208\">",
"       picture 1",
"      </a>",
"      ). In contrast, acute pancreatitis diffusely involves a large portion of the entire pancreas with a predominantly neutrophilic inflammatory response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical features and diagnosis of chronic pancreatitis. The etiology, pathogenesis, complications, and treatment of this disorder in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two primary clinical manifestations of chronic pancreatitis are abdominal pain and pancreatic insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain is a dominant feature of chronic pancreatitis. The pain is typically epigastric, often radiates to the back, is occasionally associated with nausea and vomiting, and may be partially relieved by sitting upright or leaning forward. The pain is often worse 15 to 30 minutes after eating. Early in the course of chronic pancreatitis, the pain may occur in discrete attacks; as the condition progresses, the pain tends to become more continuous.",
"   </p>",
"   <p>",
"    The pain pattern in chronic pancreatitis varies among patients. This was illustrated in a prospective cohort of 207 patients with alcoholic chronic pancreatitis in which two typical pain patterns were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/2\">",
"     2",
"    </a>",
"    ]. The first was characterized by episodes of pain (usually lasting less than 10 days) with pain free intervals lasting from months to more than a year. The second pattern was characterized by prolonged periods of daily pain or clusters of severe pain exacerbations often requiring repeated hospitalizations.",
"   </p>",
"   <p>",
"    In addition, although abdominal pain is the most consistent finding in patients with chronic pancreatitis, it may be absent in some cases. In one series, for example, 20 percent of patients with chronic pancreatitis presented with evidence of pancreatic exocrine or endocrine dysfunction in the absence of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/3\">",
"     3",
"    </a>",
"    ]. These findings are consistent with a second study in which 45 percent of asymptomatic alcoholics had evidence of chronic pancreatitis on postmortem examination [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pancreatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pancreatic exocrine dysfunction cannot properly digest complex foods or absorb partially digested breakdown products. Nevertheless, clinically significant protein and fat deficiencies do not occur until",
"    <strong>",
"     over 90 percent",
"    </strong>",
"    of pancreatic function is lost [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Fat malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatorrhea usually occurs prior to protein deficiencies since lipolytic activity decreases faster than proteolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/6\">",
"     6",
"    </a>",
"    ]. The clinical manifestations of fat malabsorption include loose, greasy, foul smelling stools that are difficult to flush. Malabsorption of the fat soluble vitamins (A, D, E, K) and vitamin B12 may also occur, although clinically symptomatic vitamin deficiency is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pancreatic diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose intolerance occurs with some frequency in chronic pancreatitis, but overt diabetes mellitus usually occurs late in the course of disease. Patients with chronic calcifying disease, particularly those who develop early calcifications, may develop diabetes more frequently than those with chronic noncalcifying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Diabetes is also more likely to occur in patients with a family history of type 1 or type 2 diabetes; this observation suggests a role for an underlying decrease in pancreatic reserve or in insulin responsiveness. Pancreatic surgery (including drainage or pancreaticoduodenectomy) does not appear to increase the risk of diabetes. Exceptions include distal pancreatectomy and significant pancreatic resection in the setting of extensive pancreatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes which develops in patients with chronic pancreatitis is usually insulin requiring. However, it is different from typical type 1 diabetes in that the pancreatic alpha cells, which produce glucagon, are also affected; as a result, there is an increased risk of hypoglycemia, both treatment related and spontaneous. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .) Diabetic ketoacidosis and nephropathy are rare; neuropathy and retinopathy occur more frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis also may be associated with a variety of complications. These include pseudocyst formation, bile duct or duodenal obstruction, pancreatic ascites or pleural effusion, splenic vein thrombosis, pseudoaneurysms, and, as will be discussed below, pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    .) Patients may also develop acute attacks of pancreatitis, particularly alcoholics who continue drinking. Acute pancreatitis should be suspected in patients with chronic pancreatitis who develop a sudden worsening or changing pattern of symptoms (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69116 \" href=\"UTD.htm?1/59/1968\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic pancreatitis can be challenging since laboratory studies and imaging procedures may be normal. In addition, patients may have symptoms suggestive of chronic pancreatitis but in fact have pancreatic carcinoma. On the other hand, the classic triad of pancreatic calcifications, steatorrhea, and diabetes mellitus strongly suggests the diagnosis, but are usually seen together only in late, very advanced disease. The diagnosis is confirmed if there are calcifications within the pancreas on abdominal plain films or computed tomography (CT) scan, an abnormal pancreatogram revealing beading of the main pancreatic duct or ectatic side branches, or an abnormal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    pancreatic function test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancer is the primary diagnosis that must be considered in patients suspected of having chronic pancreatitis. The differential diagnosis also includes autoimmune pancreatitis, lymphoma, and pancreatic endocrine tumors. Acute pancreatitis may also be difficult to distinguish from chronic pancreatitis in some patients.",
"   </p>",
"   <p>",
"    There are some data to suggest that chronic pancreatitis is associated with an increased risk of developing pancreatic carcinoma. In a report from the International Pancreatitis Study Group, 2015 patients with chronic pancreatitis were followed for a mean of 7.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/11\">",
"     11",
"    </a>",
"    ]. A total of 56 pancreatic cancers were identified. The expected number of cases of cancer calculated from country-specific incidence data and adjusted for age and sex was 2.13, yielding a standardized incidence ratio (the ratio of observed to expected cases) of 26.3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings suggestive of possible pancreatic cancer in a patient thought or known to have chronic pancreatitis include older age, absence of a history of alcohol use, weight loss, a protracted flare of symptoms, and the onset of significant constitutional symptoms. Supporting data for malignancy include a pancreatic duct stricture greater than 10 mm in length on endoscopic retrograde cholangiopancreatography (ERCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/12\">",
"     12",
"    </a>",
"    ]. Markers such as CA 19-9 and carcinoembryonic antigen (CEA) are helpful if abnormal, but normal values do not rule out pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of amylase and lipase may be slightly elevated in patients with chronic pancreatitis, but are more commonly normal for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pancreatitis is a patchy, focal disease, leading to a minimal increase in pancreatic enzymes within the blood.",
"     </li>",
"     <li>",
"      There is frequently significant fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef76728 \" href=\"UTD.htm?36/21/37208\">",
"       picture 1",
"      </a>",
"      ), resulting in decreased abundance of these enzymes within the pancreas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, serum measurements of amylase or lipase should be reserved only for the diagnosis of acute pancreatitis and not chronic pancreatitis where they are neither diagnostic nor prognostic. It is not unusual that a patient with elevated amylase or lipase values &lt;3 times the upper limit of normal is labeled as having chronic pancreatitis when, in fact, these are non-diagnostic.",
"   </p>",
"   <p>",
"    The complete blood count, electrolytes, and liver function tests are typically normal. Elevations of serum bilirubin and alkaline phosphatase suggest compression of the intrapancreatic portion of the bile duct by edema, fibrosis, or pancreatic cancer. Markers of autoimmune chronic pancreatitis include an elevated ESR, IgG4, rheumatoid factor, ANA, and anti-smooth muscle antibody titer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Steatorrhea should no longer be diagnosed qualitatively by Sudan staining of feces since it is nonspecific. A 72-hour quantitative fecal fat determination is the gold standard. The quantitative test is usually performed over 72 hours; excretion of more than 7 g of fat per day is diagnostic of malabsorption, although patients with steatorrhea often have values greater than 10",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In the proper clinical setting (eg, in a patient with typical symptoms of abdominal pain), confirmation of increased fecal fat excretion may be sufficient to diagnose chronic pancreatitis.",
"   </p>",
"   <p>",
"    Measurement of fecal elastase can be helpful for evaluating pancreatic exocrine dysfunction. Among pancreatic function tests, fecal elastase measurement is the most sensitive and specific, especially in the early phases of pancreatic insufficiency. In addition, its values are independent of pancreatic enzyme replacement therapy and require only a single random stool sample. According to unpublished data from the manufacturer, values less than 200",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    are suggestive of pancreatic insufficiency (sensitivity and specificity of 93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies that may be useful in chronic pancreatitis include abdominal plain films, transabdominal ultrasound, CT scan, magnetic resonance imaging",
"    <span class=\"nowrap\">",
"     (MRI/MRCP),",
"    </span>",
"    endoscopic retrograde cholangiopancreatography (ERCP), and endoscopic ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcifications within the pancreatic duct are present on plain film in approximately 30 percent of patients with chronic pancreatitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52624 \" href=\"UTD.htm?28/48/29455\">",
"     image 2",
"    </a>",
"    ). Calcium deposition is most common with alcoholic pancreatitis, but is also seen in the hereditary and tropical forms of the disorder; it is rare in idiopathic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=see_link\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     CT, MRI, and US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal ultrasonography (US), CT scan, and MRI may show calcifications, ductal dilatation, enlargement of the pancreas, and fluid collections (eg, pseudocysts) adjacent to the gland (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68600 \" href=\"UTD.htm?15/63/16368\">",
"     image 3",
"    </a>",
"    ). The sensitivity and specificity of ultrasound for the diagnosis of chronic pancreatitis are 60 to 70 percent and 80 to 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/16\">",
"     16",
"    </a>",
"    ]. The corresponding values for CT scanning are 75 to 90 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/17\">",
"     17",
"    </a>",
"    ]. Magnetic resonance cholangiopancreatography (MRCP) is becoming the diagnostic test of choice since it can demonstrate calcifications and pancreatic duct obstruction consistent with chronic pancreatitis. In addition, no radiation risk is involved. MRI may also be helpful for diagnosis of a rare segmental form of chronic pancreatitis (Groove pancreatitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    -enhanced MRCP is being increasingly studied for evaluation of pancreatic exocrine function and in the early diagnosis of pancreatitis. The available data suggest that it may enhance visualization of the pancreatic duct, but whether it aids in the diagnosis of chronic pancreatitis remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with advanced chronic pancreatitis may have pancreatic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the most common cause of pancreatic atrophy is aging, in which case it affects the gland diffusely and is common in slim, elderly patients. Other causes of pancreatic atrophy include prior necrotizing pancreatitis, cystic fibrosis, Shwachman-Diamond syndrome, and advanced hemochromatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link\">",
"     \"Shwachman-Diamond syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;ERCP has frequently been the test of choice for the diagnosis of chronic pancreatitis when calcifications are not present on a plain film of the abdomen and there is no evidence of steatorrhea. However, with the advances in the quality of MRCP in visualizing the pancreatic ducts (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    ), many centers are limiting the use of ERCP to cases with the potential need of therapeutic intervention (see",
"    <a class=\"local\" href=\"#H13\">",
"     'CT, MRI, and US'",
"    </a>",
"    above). Characteristic beading of the main pancreatic duct and ectatic side branches is diagnostic of chronic pancreatitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62322 \" href=\"UTD.htm?9/31/9727\">",
"     image 4",
"    </a>",
"    ). One classification system, the Cambridge classification, has divided patients into three categories based upon ductal changes on ERCP: equivocal changes (Cambridge I); mild to moderate changes (Cambridge II); and considerable changes (Cambridge III). In one report, this classification scheme correlated with the degree of pancreatic dysfunction: no patients with normal ducts on ERCP had functional impairment, while 50 percent of those with Cambridge II changes suffered from pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some patients with early chronic pancreatitis have a normal pancreatogram. Thus, unless there have been longstanding symptoms (eg, more than four years), a normal study should not rule out the diagnosis of chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/22\">",
"     22",
"    </a>",
"    ]. If the disorder is suspected despite a normal ERCP, other imaging studies (eg, endoscopic ultrasound) or pancreatic function testing should be considered, depending upon individual expertise with these techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Endoscopic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasonography (EUS) may be as sensitive as ERCP or pancreatic function testing, but requires a highly skilled gastroenterologist [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The most predictive endosonographic feature is the presence of stones. Other suggestive features include: visible side branches, cysts, lobularity, an irregular main pancreatic duct, hyperechoic foci and strands, dilation of the main pancreatic duct, and hyperechoic margins of the main pancreatic duct. Many endosonographers consider the presence of four or more of these features to be highly suggestive of chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=see_link\">",
"     \"Endoscopic ultrasound in chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pancreatic function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several invasive and noninvasive tests are available for the diagnosis of pancreatic insufficiency, which can be classified as direct or indirect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=see_link\">",
"     \"Pancreatic exocrine function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct tests involve the stimulation of the pancreas through the administration of a meal or hormonal secretagogues, after which duodenal fluid is collected and analyzed to quantify normal pancreatic secretory content (ie, enzymes, and bicarbonate). Only a few specialized centers perform these tests. Their main role is in the diagnosis of early chronic pancreatitis in patients with compatible clinical features but without characteristic radiographic findings.",
"     </li>",
"     <li>",
"      Indirect tests measure the consequences of pancreatic insufficiency and are more widely available. However, they depend upon the consequences of pancreatic maldigestion, which are generally not apparent until normal enzyme secretory output has declined by more than 90 percent. Thus, they are insensitive to early pancreatic insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past few years, genetic mutations have been associated with chronic pancreatitis. These genes include the CFTR gene responsible for cystic fibrosis, SPINK-1, which encodes for trypsin inhibitor, and the PRSS-1 gene linked to hereditary pancreatitis.",
"   </p>",
"   <p>",
"    In a study where extensive sequencing of the CFTR gene was performed in conjunction with functional analyses, 44 percent of patients with idiopathic chronic pancreatitis were found to have at least one variant in the CFTR gene which was associated with CFTR dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/27\">",
"     27",
"    </a>",
"    ]. The fact that 22 percent of healthy controls had at least one variant in that study combined with the data that over 2000 variants (ie, not disease proven mutations and thus of unknown significance) have been detected in the CFTR gene by extensive sequencing, indicates that CF genotyping should not be performed routinely to diagnose a patient with chronic pancreatitis. Alternatively, sweat chloride testing may be of benefit since it assesses CFTR function and does not rely on full gene sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/28\">",
"     28",
"    </a>",
"    ]. Up to 10 percent of patients will have abnormal results, which should prompt further investigation of occult male infertility or lung disease and may warrant professional genetic counseling.",
"   </p>",
"   <p>",
"    SPINK-1 mutations are present in 23 percent of patients with chronic pancreatitis but are seen in 2 percent of healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30935/abstract/29\">",
"     29",
"    </a>",
"    ]. In conjunction with the finding that homozygous mutations can be found in healthy individuals, testing for this gene is presently not of diagnostic or therapeutic benefit and hence not recommended.",
"   </p>",
"   <p>",
"    PRSS-1 mutations can be diagnostic of hereditary pancreatitis which can present with recurrent acute episodes of pancreatitis and progress to the chronic form. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\", section on 'Hereditary pancreatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/45/26322?source=see_link\">",
"       \"Patient information: Chronic pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two primary clinical manifestations of chronic pancreatitis are abdominal pain and pancreatic insufficiency. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of chronic pancreatitis can be challenging since laboratory studies and imaging procedures may be normal. In addition, patients may have symptoms suggestive of chronic pancreatitis but in fact have pancreatic carcinoma. On the other hand, the classic triad of pancreatic calcifications, steatorrhea, and diabetes mellitus strongly suggests the diagnosis. The diagnosis is confirmed if there are calcifications within the pancreas on abdominal plain films or computed tomography (CT) scan, an abnormal pancreatogram revealing beading of the main pancreatic duct or ectatic side branches, or an abnormal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      pancreatic function test. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One approach to the evaluation of a patient with suspected chronic pancreatitis in whom the laboratory evaluation is normal is to consider an abdominal imaging study. Contrast enhanced CT scan can rule out other causes of pain such as malignancy, or complications of pancreatitis including pseudocysts. In settings where magnetic resonance cholangiopancreatography (MRCP) is available and of high quality, it may be the imaging test of choice, allowing for assessment for ductal changes and potentially obviating the need for an endoscopic retrograde cholangiopancreatography (ERCP). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      pancreatic function testing or endoscopic ultrasound should be considered in patients with normal imaging who are suspected to have chronic pancreatitis. Secretin pancreatic function testing and endoscopic ultrasound are not needed to diagnose chronic pancreatitis in patients who have pancreatic steatorrhea confirmed by a stool elastase measurement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Endoscopic ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Pancreatic function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine full genetic analyses of CFTR and SPINK-1 are not recommended since they are not necessarily diagnostic for chronic pancreatitis, are expensive, do not generally alter management, and may result in inappropriate labeling of an individual as having cystic fibrosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/1\">",
"      Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med 1995; 332:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/2\">",
"      Ammann RW, Muellhaupt B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology 1999; 116:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/3\">",
"      Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994; 107:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/4\">",
"      Clark E. Pancreatitis in acute and chronic alcoholism. Am J Dig Dis 1942; 9:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/5\">",
"      DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/6\">",
"      Mergener K, Baillie J. Chronic pancreatitis. Lancet 1997; 350:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/7\">",
"      Toskes PP, Hansell J, Cerda J, Deren JJ. Vitamin B 12 malabsorption in chronic pancreatic insufficiency. N Engl J Med 1971; 284:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/8\">",
"      Del Prato S, Tiengo A. Pancreatic diabetes. Diabetes Reviews 1993; 1:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/9\">",
"      Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000; 119:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/10\">",
"      Ammann RW, Akovbiantz A, Largiader F, Schueler G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology 1984; 86:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/11\">",
"      Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/12\">",
"      Shemesh E, Czerniak A, Nass S, Klein E. Role of endoscopic retrograde cholangiopancreatography in differentiating pancreatic cancer coexisting with chronic pancreatitis. Cancer 1990; 65:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/13\">",
"      Keim V, Teich N, Moessner J. Clinical value of a new fecal elastase test for detection of chronic pancreatitis. Clin Lab 2003; 49:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/14\">",
"      Walkowiak J, Herzig KH, Strzykala K, et al. Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. Pediatrics 2002; 110:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/15\">",
"      Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/16\">",
"      Bolondi L, Li Bassi S, Gaiani S, Barbara L. Sonography of chronic pancreatitis. Radiol Clin North Am 1989; 27:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/17\">",
"      Luetmer PH, Stephens DH, Ward EM. Chronic pancreatitis: reassessment with current CT. Radiology 1989; 171:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/18\">",
"      Balakrishnan V, Chatni S, Radhakrishnan L, et al. Groove pancreatitis: a case report and review of literature. JOP 2007; 8:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/19\">",
"      Blasbalg R, Baroni RH, Costa DN, Machado MC. MRI features of groove pancreatitis. AJR Am J Roentgenol 2007; 189:73.",
"     </a>",
"    </li>",
"    <li>",
"     Schmidt G. Pancreas. In: Differential diagnosis in ultrasound: A teaching atlas, Georg Thieme Verlag, Stuttgart, Germany 2006. p.146.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/21\">",
"      Bozkurt T, Braun U, Leferink S, et al. Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis. Gut 1994; 35:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/22\">",
"      Axon AT, Classen M, Cotton PB, et al. Pancreatography in chronic pancreatitis: international definitions. Gut 1984; 25:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/23\">",
"      Zuccaro G Jr, Sivak MV Jr. Endoscopic ultrasonography in the diagnosis of chronic pancreatitis. Endoscopy 1992; 24 Suppl 1:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/24\">",
"      Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc 1998; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/25\">",
"      Wallace MB, Hawes RH, Durkalski V, et al. The reliability of EUS for the diagnosis of chronic pancreatitis: interobserver agreement among experienced endosonographers. Gastrointest Endosc 2001; 53:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/26\">",
"      Kahl S, Glasbrenner B, Leodolter A, et al. EUS in the diagnosis of early chronic pancreatitis: a prospective follow-up study. Gastrointest Endosc 2002; 55:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/27\">",
"      Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 2005; 118:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/28\">",
"      Ooi CY, Gonska T, Durie PR, Freedman SD. Genetic testing in pancreatitis. Gastroenterology 2010; 138:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30935/abstract/29\">",
"      Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5649 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-A295DD27D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30935=[""].join("\n");
var outline_f30_13_30935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pancreatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Fat malabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pancreatic diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Plain films",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - CT, MRI, and US",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pancreatic function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5649|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/59/1968\" title=\"diagnostic image 1\">",
"      Acute pancreatitis superimposed upon chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/48/29455\" title=\"diagnostic image 2\">",
"      Pancreatic calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/63/16368\" title=\"diagnostic image 3\">",
"      Calcified pancreas CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/31/9727\" title=\"diagnostic image 4\">",
"      ERCP in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5649|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/21/37208\" title=\"picture 1\">",
"      Chron pancreatitis H and E",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=related_link\">",
"      Endoscopic ultrasound in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=related_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=related_link\">",
"      Pancreatic exocrine function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/45/26322?source=related_link\">",
"      Patient information: Chronic pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30936="BM biopsy B cell ALL";
var content_f30_13_30936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bone marrow biopsy of a case of B cell acute lymphoblastic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow biopsy shows total replacement of normal hematopoietic cells with lymphoblasts that shows convoluted or folded nuclei. Hematoxylin and eosin, 100x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30936=[""].join("\n");
var outline_f30_13_30936=null;
var title_f30_13_30937="Olanzapine and fluoxetine: Drug information";
var content_f30_13_30937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olanzapine and fluoxetine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/62/42981?source=see_link\">",
"    see \"Olanzapine and fluoxetine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Symbyax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor;",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Lower doses (olanzapine 3-6 mg/fluoxetine 25 mg) should be used in patients predisposed to hypotension, with hepatic impairment, with combined factors for reduced metabolism (females, the elderly, nonsmokers), or enhanced sensitivity to olanzapine; dose adjustments should be made with caution in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Depression associated with bipolar I disorder:",
"     </b>",
"     Initial: Olanzapine 6 mg/fluoxetine 25 mg once daily in the evening. Dosing range: Olanzapine 6-12 mg/fluoxetine 25-50 mg. Safety of daily doses of olanzapine &gt;18 mg/fluoxetine &gt;75 mg have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment-resistant depression:",
"     </b>",
"     Initial: Olanzapine 6 mg/fluoxetine 25 mg once daily in the evening. Dosing range: Olanzapine 6-18 mg/fluoxetine 25-50 mg. Safety of daily doses of olanzapine &gt;18 mg/fluoxetine &gt;75 mg have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When using individual components of fluoxetine with olanzapine rather than fixed dose combination product (Symbyax&reg;), approximate dosage correspondence is as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax&reg; 3/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olanzapine 5 mg + fluoxetine 20 mg = Symbyax&reg; 6/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax&reg; 12/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olanzapine 5 mg + fluoxetine 50 mg = Symbyax&reg; 6/50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax&reg; 12/50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of olanzapine/fluoxetine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 5 weeks to elapse between discontinuing olanzapine/fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate olanzapine/fluoxetine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving olanzapine/fluoxetine and potential benefits outweigh potential risks, discontinue olanzapine/fluoxetine promptly and administer linezolid or I.V. methylene blue. Monitor for SS for 5 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume olanzapine/fluoxetine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: Olanzapine 3-6 mg/fluoxetine 25 mg once daily in the evening; use caution adjusting dose (metabolism may be decreased). Safety and efficacy have not been established in patients &gt;65 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F203427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: Olanzapine 3-6 mg/fluoxetine 25 mg once daily in the evening; use caution adjusting dose (metabolism may be decreased).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, oral: 3/25: Olanzapine 3 mg and fluoxetine 25 mg; 6/25: Olanzapine 6 mg and fluoxetine 25 mg; 6/50: Olanzapine 6 mg and fluoxetine 50 mg; 12/25: Olanzapine 12 mg and fluoxetine 25 mg; 12/50: Olanzapine 12 mg and fluoxetine 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symbyax&reg; 3/25: Olanzapine 3 mg and fluoxetine 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symbyax&reg; 6/25: Olanzapine 6 mg and fluoxetine 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symbyax&reg; 6/50: Olanzapine 6 mg and fluoxetine 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symbyax&reg; 12/25: Olanzapine 12 mg and fluoxetine 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symbyax&reg; 12/50: Olanzapine 12 mg and fluoxetine 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089140.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089140.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules should be taken once daily in the evening; may be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depressive episodes associated with bipolar I disorder; treatment-resistant depression (unresponsive to 2 trials of different antidepressants in the current episode)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Symbyax&reg; may be confused with Cymbalta&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported with combination product (also see individual agents):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (14%), fatigue (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperprolactinemia (28%), bicarbonate decreased (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (25%), appetite increased (20%), xerostomia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (9%), edema (3%), vasodilation (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sedation (8%), attention disturbance (5%), hypersomnia (5%), restlessness (4%), lethargy (3%), pain in extremity (3%), fever (2%), nervousness (2%), pain (2%), thinking abnormal (2%), chills (&ge;1%), amnesia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Photosensitivity (&ge;1%), ecchymosis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia (3%), uric acid levels increased (3%), hypophosphatemia (2%), breast pain (&ge;1%), menorrhagia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (3%), abdominal distension (2%), diarrhea (&ge;1%), taste perversion (&ge;1%), weight loss (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Erectile dysfunction (2%), urinary frequency (&ge;1%), urinary incontinence (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased (3%), lymphocytopenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (9%), arthralgia (4%),  weakness (3%), stiffness (2%), neck rigidity (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Glucosuria (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined: Alkaline phosphate increased, AST increased, cholesterol increased, GGT increased, hyperglycemia, hyponatremia, orthostatic hypotension, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports (limited to significant or life-threatening): Agranulocytosis, amenorrhea, anorgasmia, anemia, ataxia, bilirubinemia, bradycardia, breast enlargement,  coma, creatine phosphokinase increased, creatinine increased, DVT, dysarthria, dystonia, epistaxis, erectile dysfunction, exfoliative dermatitis, galactorrhea, gastrointestinal hemorrhage, gynecomastia,  intestinal obstruction, hypokinesia, hypomenorrhea, lactation disorder, leukopenia, libido decreased, menstruation delayed, myoclonus, neutropenia, oligomenorrhea, osteoporosis, pancreatitis, pulmonary embolism, purpura, QT-interval prolongation, rhabdomyolysis, sexual dysfunction, tachycardia, thrombocytopenia, urinary retention, urinary urgency",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of MAO inhibitors intended to treat psychiatric disorders (concurrently, within 5 weeks of discontinuing olanzapine/fluoxetine, or within 2 weeks of discontinuing the MAO inhibitor); initiation of olanzapine/fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (",
"     <b>",
"      Note:",
"     </b>",
"     Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine.)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      This combination is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic events and rash: Fluoxetine use has been associated with occurrences of significant rash and allergic events, including vasculitis, lupus-like syndrome, laryngospasm, anaphylactoid reactions, and pulmonary inflammatory disease. Discontinue if underlying cause of rash cannot be identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Olanzapine may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems (including narrow-angle glaucoma). Relative to other neuroleptics, olanzapine has a moderate potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of olanzapine for the unapproved use in elderly patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/Aspiration: Has been associated with antipsychotic use; use with caution in patients at risk of pneumonia (eg, Alzheimer&rsquo;s disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Olanzapine may have a greater association with hyperglycemia than other atypical antipsychotics. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodic assessment of glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Increases in cholesterol and triglycerides have been noted. Use olanzapine with caution in patients with pre-existing abnormal lipid profile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Increases prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown. Clinical manifestations of increased prolactin levels included menstrual-, sexual- and breast-related events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Moderate to highly sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Significant weight gain (&gt;7% of baseline weight) has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction, ischemic heart disease, or hypercholesterolemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related behavioral disorders treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Olanzapine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; lowest starting dose recommended; may increase transaminases (primarily ALT).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      This combination is FDA approved for the treatment of depressive episodes associated with bipolar disorder.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal disease; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Use caution with concurrent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; both agents may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of olanzapine in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Olanzapine may also be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Olanzapine levels may be lower in patients who smoke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Antidepressant efficacy with treatment &gt;8 weeks duration has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long half-life: Due to the long half-life of fluoxetine and its metabolites, the effects and interactions noted may persist for prolonged periods following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: FLUoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose should be reduced by at least half, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: OLANZapine may enhance the adverse/toxic effect of Benzodiazepines.  Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of OLANZapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: FLUoxetine may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: FLUoxetine may enhance the QTc-prolonging effect of Haloperidol. FLUoxetine may increase the serum concentration of Haloperidol.  Management: Consider alternatives to this combination when available.  If the combination is used, monitor for evidence of QTc prolongation and increased systemic haloperidol concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May enhance the sedative effect of OLANZapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NiMODipine: FLUoxetine may increase the serum concentration of NiMODipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of FLUoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: FLUoxetine may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: FLUoxetine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F203421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A decrease in fetal weight, testicular degeneration and atrophy, depletion of epididymal sperm, and infertility in males was reported in some animal reproduction studies using this combination. Use during pregnancy is not recommended. Refer to individual agents for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F203418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F203415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (OLANZapine-FLUoxetine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-25 mg (30): $317.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-25 mg (30): $434.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-50 mg (30): $434.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-25 mg (30): $654.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-50 mg (30): $654.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Symbyax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-25 mg (30): $353.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-25 mg (30): $482.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-50 mg (30): $482.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-25 mg (30): $727.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-50 mg (30): $727.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F203404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status; abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS); signs and symptoms of depression, anxiety, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), sleep; signs/symptoms of serotonin syndrome and/or NMS; liver function tests in patients with hepatic disease; complete blood count in patients at risk for neutropenia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Symbyax (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Olanzapine is a second generation thienobenzodiazepine antipsychotic which displays potent antagonism of serotonin 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     , dopamine D",
"     <sub>",
"      1-4",
"     </sub>",
"     , histamine H",
"     <sub>",
"      1",
"     </sub>",
"     and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors. Olanzapine shows moderate antagonism of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     and muscarinic M",
"     <sub>",
"      1-5",
"     </sub>",
"     receptors, and weak binding to GABA-A, BZD, and beta-adrenergic receptors. Fluoxetine inhibits CNS neuron serotonin reuptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors. The enhanced antidepressant effect of the combination may be due to synergistic increases in serotonin, norepinephrine, and dopamine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at file://www.psychiatryonline.com/content.aspx?aid=501001",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/13/30937/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10088 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30937=[""].join("\n");
var outline_f30_13_30937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709178\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203424\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203437\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203425\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203426\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203427\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203407\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203394\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874939\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203410\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203409\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203435\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203413\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203396\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299783\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203400\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203421\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203402\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203431\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203418\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203415\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203404\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961923\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203395\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203412\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/62/42981?source=related_link\">",
"      Olanzapine and fluoxetine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30938="Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults";
var content_f30_13_30938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30938/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30938/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30938/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/13/30938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/13/30938/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/13/30938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune thrombocytopenia (also called idiopathic thrombocytopenic purpura, immune thrombocytopenic purpura, ITP) is an acquired disorder. There are only two criteria required in order to make this diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated thrombocytopenia is present. The rest of the complete blood count, including an examination of the peripheral blood smear, is entirely normal, unless other coincidental abnormalities are present, such as iron deficiency.",
"     </li>",
"     <li>",
"      Clinically apparent associated conditions (eg, systemic lupus erythematosus, antiphospholipid syndrome, chronic lymphocytic leukemia) are not present. Patients with these associated conditions are described as having \"secondary immune thrombocytopenia\" [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/7\">",
"       7",
"      </a>",
"      ]. Also, drugs, including herbal remedies and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      -containing beverages that may cause thrombocytopenia are NOT apparent etiologies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and differential diagnosis of ITP will be reviewed here. The treatment and prognosis of this disorder and the clinical manifestations, diagnosis, treatment, and prognosis of childhood ITP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of ITP is related to a combination of increased platelet destruction along with inhibition of megakaryocyte platelet production via the production of specific IgG autoantibodies by the patient's B cells, most often directed against platelet membrane glycoproteins such as",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/2,8-11\">",
"     2,8-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inciting events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of ITP is unclear, but is thought to include genetic as well as acquired factors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/7,12,13\">",
"     7,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some cases of ITP are associated with a preceding viral infection. It is possible that resulting anti-viral antibodies cross-react with platelet glycoproteins. Infection with HIV, HCV, CMV [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/14\">",
"       14",
"      </a>",
"      ], and VZV may be associated with such antibodies therefore cause secondary ITP. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Onset after infection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Alterations in the immune response might induce loss of peripheral tolerance and promote the development of self-reactive antibodies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'B and T cell responses in ITP'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Abnormalities in the immune system may predispose to the development of autoimmune thrombocytopenia. Examples include the antiphospholipid syndrome, systemic lupus erythematosus, Evans syndrome, post-hematopoietic cell transplantation ITP, sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/15\">",
"       15",
"      </a>",
"      ], and the secondary ITP seen in patients with chronic lymphocytic leukemia and other low-grade lymphoproliferative disorders, especially those treated with purine analogs, and the autoimmune lymphoproliferative syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/7,16\">",
"       7,16",
"      </a>",
"      ]. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although ITP has been reported in association with nonhematologic malignancies, especially breast cancer, the association is likely coincidental [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     B and T cell responses in ITP",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell autoimmune IgG responses in ITP appear to be driven by CD4+ helper T cells reacting to platelet membrane glycoprotein epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/21\">",
"     21",
"    </a>",
"    ], possibly involving CD40:CD40L co-stimulation processes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/22\">",
"     22",
"    </a>",
"    ], with splenic macrophages as the major antigen-presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link&amp;anchor=H5#H5\">",
"     \"The humoral immune response\", section on 'Activation signals'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link&amp;anchor=H18#H18\">",
"     \"Megakaryocyte biology and the production of platelets\", section on 'Immune thrombocytopenic purpura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following pathogenic loop has been suggested to explain this process [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membrane",
"      <span class=\"nowrap\">",
"       GPIIb/IIIa",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       GPIb/IX",
"      </span>",
"      of phagocytosed platelets are processed, and their digested peptides are presented by macrophages to autoreactive HLA-restricted CD4+ T cells.",
"     </li>",
"     <li>",
"      These T cells become activated when T cell receptors recognize the HLA-DR antigenic peptide complex on the antigen-presenting macrophages.",
"     </li>",
"     <li>",
"      The activated T cells secrete IL-6 and upregulate CD154 expression, exerting helper activity on autoreactive antibody-producing B cells. The latter are restricted B cell clones that undergo proliferation and somatic mutation under antigenic pressure.",
"     </li>",
"     <li>",
"      The autoantibodies thus produced bind to platelets, and the opsonized platelets are phagocytosed mainly by splenic macrophages, perhaps aided by complement activation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/25\">",
"       25",
"      </a>",
"      ], thus completing the loop. The autoantibodies can also bind to megakaryocytes, decreasing overall platelet production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of interactions between B and T cells in ITP was illustrated in a study which evaluated T cell subset changes in 30 patients with chronic ITP and elevated levels of platelet-associated immunoglobulin, who were treated with the B cell depleting antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/26\">",
"     26",
"    </a>",
"    ]. Pre-treatment abnormalities in the T cell compartment of these patients reverted in responders to rituximab, whereas they remained unchanged in nonresponders. This study suggests that depletion of B cells may reduce co-stimulation of pathogenic T cell clones in the responders.",
"   </p>",
"   <p>",
"    Alternative mechanisms involving T cells, including T cell-mediated cytotoxicity and defects in the number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function of regulatory T cells (Tregs) have also been postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/27-36\">",
"     27-36",
"    </a>",
"    ]. The latter mechanism is supported by a study showing a reduced number and defective suppressive capacity of Tregs in ITP patients compared with controls, and restored Treg numbers and regulatory function, especially in responders, following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies are not demonstrable in all patients with ITP and assays for antiplatelet antibodies have not yet proven to be important for management decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/2,3,37,38\">",
"     2,3,37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link&amp;anchor=H18#H18\">",
"     \"Megakaryocyte biology and the production of platelets\", section on 'Immune thrombocytopenic purpura'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;ITP is a common acquired bleeding disorder. The incidence of ITP in children is greater than the incidence among adults (",
"    <a class=\"graphic graphic_figure graphicRef78231 \" href=\"UTD.htm?4/13/4318\">",
"     figure 1",
"    </a>",
"    ). In children, the incidence of ITP in boys and girls is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Denmark survey from 1973 to 1995 estimated the annual incidence of ITP among adults to be 22 per million per year, using a platelet count cut-off of",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/40\">",
"     40",
"    </a>",
"    ]. The incidence rate rose during the study period, due primarily to increased recognition of asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this incidence estimate primarily includes symptomatic patients. This is an important issue since, in two large case series, 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/41\">",
"     41",
"    </a>",
"    ] and 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/42\">",
"     42",
"    </a>",
"    ] of adults were discovered to have ITP when they had no bleeding symptoms. Therefore, the total incidence of ITP among adults is likely to be greater than 22 per million per year. This was shown in a UK population-based study of patients all diagnosed with ITP from 1990 through 2005. The crude ITP incidence for this period was 39 and 44 per million per year for men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because ITP in adults is typically a chronic disease, the prevalence exceeds the incidence. In one estimate of the prevalence of ITP in the US, the estimate was approximately 100 per million per year, with age cohorts ranging from 41 to 160 per million per year, with the highest values seen in the oldest age cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many reports have suggested that, among adults with ITP, approximately 70 percent are women and 72 percent of these women are less than 40 years of age. However, the Denmark survey reported a sex difference in the incidence of ITP only for those &lt;60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/40\">",
"     40",
"    </a>",
"    ], while a total lack of sex difference was noted in a population-based cohort from the Northern Health Region of England of newly-presenting adults with ITP and platelet counts",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/42\">",
"     42",
"    </a>",
"    ]. The overall incidence of ITP in the latter study was 16 per million per year, with no difference between males and females in any age group, and with the highest age-specific incidence in those &gt;60 years of age.",
"   </p>",
"   <p>",
"    The findings in the Danish and English series may be due to differences in methodology, as both surveys identified all patients who met criteria for ITP, rather than those presenting with symptoms. Thus, the traditional teaching that ITP is primarily a disease of young females will have to be modified. This was shown in the UK study in which the highest incidence of ITP was found in subjects &gt;75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/43\">",
"     43",
"    </a>",
"    ]. The incidence of ITP was greater in females in the age range from 18 to 64 years, while it was greater in males for those &lt;18 as well as &gt;65 years of age.",
"   </p>",
"   <p>",
"    All published reports on the incidence of ITP have been critically reviewed, comparing the strengths and weakness of their methodology [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is marked interpatient variability in the clinical presentation of ITP. Although the onset of ITP may be acute and abrupt, it is more often insidious. Similarly, bleeding in symptomatic patients can range from petechiae and easy bruising to a severe bleeding diathesis. In addition, the clinical laboratory routine of reporting a platelet count with all requests for blood counts, which began with the introduction of automated cell counters, has resulted in the discovery of asymptomatic, mild thrombocytopenia, thereby enlarging the clinical spectrum of ITP.",
"   </p>",
"   <p>",
"    The clinical manifestations of ITP are limited to those related to excessive bleeding caused by thrombocytopenia. The bleeding manifestations of thrombocytopenia are described as mucocutaneous, to distinguish them from the delayed, slowly evolving visceral hematomas characteristic of coagulation disorders such as hemophilia (see below). Thus, in patients with thrombocytopenia due to ITP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Petechiae, purpura, and easy bruising are expected.",
"     </li>",
"     <li>",
"      Epistaxis, gingival bleeding, and menorrhagia are common.",
"     </li>",
"     <li>",
"      Overt gastrointestinal bleeding and gross hematuria are rare.",
"     </li>",
"     <li>",
"      Intracranial hemorrhage, a potentially fatal bleeding complication, is so uncommon that there is no reliable estimate of its frequency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of thrombocytopenia also vary with age. Older patients may have more severe bleeding manifestations, such as gastrointestinal bleeding and possibly intracranial hemorrhage because of comorbidities such as hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Onset after infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ITP typically present with an acute, sudden clinical onset, usually associated with a history of infection in the several weeks preceding the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. In one series, for example, infection in the three weeks prior to the onset of ITP was seen in 84 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How infection, viral or bacterial, might promote the development or worsening of ITP is uncertain, although a number of mechanisms have been postulated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virus-specific antibodies may crossreact with normal platelet antigens, and contribute to increased platelet clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Helicobacter pylori infection has been associated with ITP in some reports. Experimental observations, including the induction of platelet aggregation by certain strains of H. pylori, and cross-reactivity between platelet-associated IgG and H. pylori cytotoxin-associated gene A (CagA) protein may explain this association. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29194?source=see_link&amp;anchor=H27#H27\">",
"       \"Chronic refractory immune (idiopathic) thrombocytopenic purpura in adults\", section on 'Helicobacter pylori infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Molecular mimicry between HIV proteins and platelet",
"      <span class=\"nowrap\">",
"       GPIIb/IIIa",
"      </span>",
"      may be important in the pathogenesis of primary HIV-associated thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H4#H4\">",
"       \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Reduced platelet survival'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of autoimmune phenomena have been noted following infection with the hepatitis C virus, including immune thrombocytopenia and autoimmune hemolytic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/52\">",
"       52",
"      </a>",
"      ]. Molecular mimicry between HCV core envelope protein 1 and platelet GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      has been implicated in the genesis of HCV-associated thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H7#H7\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Autoimmune disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial products, such as lipopolysaccharides, when attached to the surface of platelets in the presence of antiplatelet antibodies, can significantly increase platelet phagocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drug-associated immune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs have been associated with the development of autoimmune disorders, such as pure red cell aplasia, autoimmune hemolytic anemia, and immune thrombocytopenia. Two of these are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the monoclonal anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in several treatment settings (eg, chronic lymphocytic leukemia, organ transplantation, multiple sclerosis) has been associated with the development of autoimmune disorders (eg, autoimmune hemolytic anemia, pure red cell aplasia), including ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. The mechanism involved may be related to the ability of this agent to cause severe immune dysregulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Alemtuzumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Alemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Purine analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of purine analogs in patients with low-grade lymphoma has been associated with an increased incidence of autoimmune hemolytic anemia and immune thrombocytopenia. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link&amp;anchor=H20#H20\">",
"     \"Autoimmune complications following purine analog therapy\", section on 'Autoimmune thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comparison with vasculitic purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defining characteristics of petechiae and purpura in thrombocytopenic patients are that they are asymptomatic and not palpable. This is an important clinical distinction from patients with vasculitis, such as Henoch-Sch&ouml;nlein purpura (IgA vasculitis) or drug hypersensitivity. In vasculitic purpura, the patient experiences a prodrome of stinging or burning. On examination, vasculitic purpura has a palpable, papular character. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H20#H20\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Clinical features suggestive of vasculitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H42#H42\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombocytopenic purpura and vasculitic purpura also have a different pattern of distribution. Thrombocytopenic purpura is consistently localized to dependent portions of the body. As a result, petechiae are most dense on the feet and ankles, fewer are present on the legs, and only scattered petechiae occur elsewhere on the body. Areas with firm subcutaneous tissue, such as the soles of the feet, are protected from petechiae, while areas with minimal subcutaneous support, such as the oral mucosa and conjunctivae, may have large bullous appearing hemorrhages (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ). In contrast, vasculitic purpura may occur in symmetrical patches without regard for a dependent distribution (",
"    <a class=\"graphic graphic_picture graphicRef62546 \" href=\"UTD.htm?29/6/29794\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparison with coagulation disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of ITP are distinct from the bleeding abnormalities that occur with a coagulation disorder. Patients with hemophilia, for example, do not have petechiae or purpura because their platelet function is normal. The most common manifestation of hemophilia is the delayed formation of a hematoma following trauma, as in a muscle or joint space. In comparison, muscle hematomas and hemarthroses rarely occur in patients with ITP (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Correlation between bleeding and the platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data that describe the risk of clinically important bleeding at different levels of thrombocytopenia. Furthermore, the correlation between bleeding symptoms and the platelet count may be in part related to the etiology of the thrombocytopenia.",
"   </p>",
"   <p>",
"    Because the pathogenesis of ITP involves accelerated platelet destruction by autoantibodies, with a compensatory increase in platelet production in some patients, circulating platelets in patients with ITP are younger and have greater hemostatic effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/60\">",
"     60",
"    </a>",
"    ]. As a result, bleeding manifestations in patients with ITP are less severe at equivalent platelet counts than in patients with thrombocytopenia due to marrow aplasia or chemotherapy-induced marrow suppression.",
"   </p>",
"   <p>",
"    There are more direct observations on patients with chemotherapy-induced marrow suppression to determine the appropriate platelet count threshold that requires platelet transfusion support. These data indicate that clinically important bleeding rarely occurs with platelet counts above",
"    <span class=\"nowrap\">",
"     10,000/microL,",
"    </span>",
"    unless the patient is febrile or has a serious systemic illness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is suggestive evidence that a similar threshold exists in ITP. Clinically important bleeding does not appear to occur in these patients unless the platelet count is less than",
"    <span class=\"nowrap\">",
"     10,000/microL;",
"    </span>",
"    even at this level, most patients do not have serious bleeding episodes (",
"    <a class=\"graphic graphic_figure graphicRef72370 \" href=\"UTD.htm?19/27/19901\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/62\">",
"     62",
"    </a>",
"    ]. These observations suggest that treatment of ITP may be unnecessary unless the platelet count is less than",
"    <span class=\"nowrap\">",
"     10,000/microL.",
"    </span>",
"    However the standard of practice for adults with ITP is that treatment is generally initiated when the platelet count is less than 30,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    because the course of the disease and risks for bleeding cannot be predicted at the time of the initial diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acquired platelet function abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;When bleeding in ITP appears to be more severe than would be suggested by the platelet count alone, the patient may (rarely) have an autoantibody that inhibits the function of platelet glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    resulting in abnormal platelet aggregation (ie, acquired Glanzmann thrombasthenia) in addition to the underlying thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H31#H31\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Acquired Glanzmann thrombasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no \"gold standard\" test that can establish the diagnosis of ITP. The diagnosis is, in part, one of exclusion, requiring that other causes of thrombocytopenia be ruled out (",
"    <a class=\"graphic graphic_table graphicRef77063 \" href=\"UTD.htm?39/51/40764\">",
"     table 2",
"    </a>",
"    ). Few diagnostic studies other than the history, physical examination, complete blood count, and examination of the blood smear are necessary.",
"   </p>",
"   <p>",
"    Overall approaches to the patient with thrombocytopenia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=see_link\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the blood smear may provide evidence for other causes of thrombocytopenia, such as the presence of schistocytes in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H25#H25\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'CBC and peripheral smear'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the peripheral blood smear is essential to exclude \"pseudothrombocytopenia\" due to the artifact of platelet agglutination induced by the standard blood count anticoagulant, EDTA&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 4",
"    </a>",
"    ). EDTA-dependent agglutinins are present in approximately 0.1 percent of people in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. This phenomenon is thought to result from a \"naturally occurring\" platelet autoantibody directed against a normally concealed epitope on the platelet membrane glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    which becomes exposed by EDTA-induced dissociation of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/68\">",
"     68",
"    </a>",
"    ]. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important for each clinical laboratory to have an established procedure for responding to artifactually low platelet counts caused by these agglutinins. An appropriate procedure is to report that an artifact due to platelet clumping is present, rather than the actual platelet count, which could be misinterpreted as true thrombocytopenia.",
"   </p>",
"   <p>",
"    Three other artifacts can affect platelet counting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cold-dependent platelet agglutinins and autoantibodies may induce \"rosetting\" of platelets around neutrophils",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      monocytes, resulting in pseudothrombocytopenia.",
"     </li>",
"     <li>",
"      Giant platelets that can occur in certain congenital thrombocytopenic disorders (",
"      <a class=\"graphic graphic_picture graphicRef72433 \" href=\"UTD.htm?17/31/17911\">",
"       picture 5",
"      </a>",
"      ) may not be recognized as platelets by some automated instruments used for blood counts, resulting in pseudothrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H7#H7\">",
"       \"Automated hematology instrumentation\", section on 'Platelet counting'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H10#H10\">",
"       \"Automated hematology instrumentation\", section on 'The optical platelet count'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryoglobulin particles may be counted as platelets, artifactually elevating the platelet count in patients who have cryoglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/69\">",
"       69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to the patient with thrombocytosis\", section on 'Spurious thrombocytosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Making a presumptive diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of ITP is made when the history (eg, lack of ingestion of a drug, beverage, food, or herbal remedy that can cause thrombocytopenia, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , including quinine in beverages such as tonic water, a sulfonamide such as sulfamethoxazole, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/70\">",
"     70",
"    </a>",
"    ]), physical examination, complete blood count, and examination of the peripheral blood smear do not suggest other etiologies for the patient's",
"    <strong>",
"     isolated",
"    </strong>",
"    thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H9#H9\">",
"     \"Drug-induced thrombocytopenia\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only recommended further tests in such patients are [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/1,71\">",
"     1,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing for HIV and HCV infection is appropriate because treatment of the underlying disease may alter the course of the thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thyroid function testing to exclude the infrequent presence of occult hyperthyroidism or hypothyroidism before elective splenectomy is performed",
"     </li>",
"     <li>",
"      Bone marrow",
"      <span class=\"nowrap\">",
"       aspiration/biopsy",
"      </span>",
"      in patients over 60 years of age to rule out myelodysplastic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/72,73\">",
"       72,73",
"      </a>",
"      ] was previously recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/1\">",
"       1",
"      </a>",
"      ] and is still considered appropriate by some hematologists [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/5\">",
"       5",
"      </a>",
"      ]. However, no studies have documented the value of bone marrow",
"      <span class=\"nowrap\">",
"       aspiration/biopsy",
"      </span>",
"      in the evaluation of patients with suspected ITP, and it was not recommended by the current American Society of Hematology guideline [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/6\">",
"       6",
"      </a>",
"      ]. However, bone marrow studies should be performed in patients responding poorly to therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prior to splenectomy in order to",
"      <span class=\"nowrap\">",
"       reevaluate/reconfirm",
"      </span>",
"      the initial diagnosis of ITP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with presumed ITP, severe thrombocytopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical bleeding, urgent hematologic consultation is most appropriate. For asymptomatic patients with modest degrees of thrombocytopenia, consultation is less urgent, but should be pursued in order to establish a baseline, should treatment be required in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antiplatelet antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Hematology ITP Practice Guideline did not recommend antiplatelet antibody studies in patients thought to have ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/1\">",
"     1",
"    </a>",
"    ], and there is still no evidence that antiplatelet antibody studies are important for the diagnosis of ITP. This recommendation is different from the common practice of many physicians, but is consistent with the absence of data that platelet antibody testing affects management decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/2\">",
"     2",
"    </a>",
"    ]. The lack of clinical value of antiplatelet antibody testing reflects limitations of laboratory methodology. The absence of detectable antiplatelet antibodies does not imply the absence of autoantibodies as the underlying pathogenesis of ITP.",
"   </p>",
"   <p>",
"    The lack of value of antibody testing can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small study compared patients with ITP to patients initially suspected of having ITP in whom an alternative diagnosis was subsequently made [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/74\">",
"       74",
"      </a>",
"      ]. Commonly used commercial tests for both platelet-bound IgG and serum platelet-bindable IgG had no predictive value.",
"     </li>",
"     <li>",
"      A larger series included 90 patients with a clinical diagnosis of ITP and 160 patients with a clinical diagnosis of incidental thrombocytopenia of pregnancy (gestational thrombocytopenia); four laboratories with expertise in platelet antibody testing were involved and eight different assays for antiplatelet antibodies were used [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/75\">",
"       75",
"      </a>",
"      ]. There was no difference between these two groups with six of the tests; a seventh test had a statistically significant distinction, but the difference was clinically unimportant because there was almost complete overlap among individual patients.",
"     </li>",
"     <li>",
"      A subset of 40 patients in the preceding study had a statistically significant distinction when glycoprotein-specific antiplatelet antibodies were assayed [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/75\">",
"       75",
"      </a>",
"      ]. In another report, however, there were variable results with platelet glycoprotein-specific antiplatelet antibody tests when the same samples from patients with ITP were studied in eight different laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In reviews of four prospective studies, antiplatelet antibody tests were positive in 49 to 66 percent of patients with ITP, but were also positive in 7 to 28 percent of patients with apparently nonimmune etiologies (eg, gestational thrombocytopenia, myelodysplastic syndrome,",
"      <span class=\"nowrap\">",
"       familial/congenital",
"      </span>",
"      thrombocytopenia) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/63,77\">",
"       63,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two studies of newer techniques demonstrated only 53 to 55 percent sensitivity for making the diagnosis of ITP and 82 to 84 percent specificity [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data provide support for the concept that thrombocytopenia in ITP is mediated by autoantibodies, but the frequency of false negative and false positive results limits the value of these tests for making clinical decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results of platelet antibody testing in ITP are also different from the standard practice in autoimmune hemolytic anemia, which is defined by the presence of a positive antibody test (ie, direct antiglobulin test [DAT], direct Coombs test). In many cases of ITP, what is being measured is \"platelet-associated IgG\", which may reflect plasma IgG acquired by platelet pincytosis rather than antiplatelet antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At this time, platelet antibody tests are",
"    <strong>",
"     not necessary",
"    </strong>",
"    for management decisions in patients with suspected ITP. Specifically, currently available tests do not distinguish ITP from secondary thrombocytopenic purpura, and a negative test does not rule out the diagnosis of ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/2,74,77,78,80,81\">",
"     2,74,77,78,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinically apparent associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thrombocytopenia and a clinically apparent associated condition causing the thrombocytopenia may have a disorder comparable to ITP. However, these patients can be distinguished from those with ITP because the clinical course is often dominated by the associated condition. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia and other lymphoproliferative disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link\">",
"       \"Autoimmune complications following purine analog therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytopenia associated with HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H2#H2\">",
"       \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus and other autoimmune disorders. Approximately 3 to 15 percent of patients with apparently isolated ITP go on to develop systemic lupus erythematosus (SLE). In one series of 115 patients who underwent splenectomy for ITP, 14 (12.5 percent) subsequently developed SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H18#H18\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the definition of ITP, the emphasis on excluding only",
"    <strong>",
"     clinically apparent",
"    </strong>",
"    associated conditions is important, because patients with typical ITP often have isolated abnormalities on serologic tests without symptoms of a systemic disorder. As an example, up to 40 percent of otherwise typical patients with ITP have positive tests for antinuclear antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/83\">",
"     83",
"    </a>",
"    ] or antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/84-87\">",
"     84-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ITP and other autoimmune phenomena (eg, autoimmune hemolytic anemia, pernicious anemia) are often seen in patients with common variable immunodeficiency (CVI) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/88\">",
"     88",
"    </a>",
"    ]. The diagnosis of ITP may be made before, at the time of, or following the diagnosis of CVI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/89\">",
"     89",
"    </a>",
"    ]. Testing for immunoglobulin levels has been suggested as a way to determine which patients with ITP also suffer from CVI. Treatment of ITP with agents resulting in further immunosuppression is relatively contraindicated when these conditions coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of antinuclear antibodies does not appear to affect the overall clinical course of these patients, but antiphospholipid antibodies are associated with a high incidence of thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal loss over the subsequent five years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients should be alerted about this increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Hematologic manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bone marrow aspiration and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the typical patient with ITP, overall bone marrow cellularity is normal, with normal erythropoiesis and myelopoiesis. Megakaryocytes are present in normal to increased numbers. In some patients, a shift towards younger megakaryocytes with lesser degrees of nuclear polyploidy and less evidence of platelet production may be noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link&amp;anchor=H18#H18\">",
"     \"Megakaryocyte biology and the production of platelets\", section on 'Immune thrombocytopenic purpura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow examination is not required in most patients with isolated thrombocytopenia and suspected ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/1,3,91\">",
"     1,3,91",
"    </a>",
"    ]. However, it should be performed in patients over the age of 60, because of concern for the presence of myelodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Myelodysplasia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4008100#H4008100\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Complete blood count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Marrow examination is also of critical importance in making a diagnosis of the rare condition, acquired pure megakaryocytic aplasia (amegakaryocytic thrombocytopenia), in which megakaryocytes are either severely reduced in number, or absent (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"     \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ITP in which patients develop thrombocytopenia without other cytopenias is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77063 \" href=\"UTD.htm?39/51/40764\">",
"     table 2",
"    </a>",
"    ). The differential diagnosis of skin lesions that may mimic the purpura seen in ITP is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H42#H42\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     TTP-HUS and DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious consequences result if thrombocytopenia as part of thrombotic thrombocytopenia purpura-hemolytic uremic syndrome (TTP-HUS) or chronic disseminated intravascular coagulation (DIC) is mistaken for ITP. These syndromes have other associated hematologic and clinical abnormalities, such as the presence of fragmented red cells (schistocytes) in TTP-HUS or abnormalities of coagulation in DIC, which should make their diagnosis quickly apparent.",
"   </p>",
"   <p>",
"    However, in some patients with TTP-HUS, only thrombocytopenia and anemia are present and the anemia may be attributed to bleeding due to the thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gestational thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common cause of thrombocytopenia is incidental thrombocytopenia of pregnancy (also termed gestational thrombocytopenia) which occurs in approximately 5 percent of women near the end of an otherwise uncomplicated pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H3#H3\">",
"     \"Thrombocytopenia in pregnancy\", section on 'Gestational thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic criteria for gestational thrombocytopenia include [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic, mild thrombocytopenia (platelet count typically",
"      <span class=\"nowrap\">",
"       &gt;70,000/microL)",
"      </span>",
"     </li>",
"     <li>",
"      No past history of thrombocytopenia (except possibly during a previous pregnancy)",
"     </li>",
"     <li>",
"      Occurrence during late gestation",
"     </li>",
"     <li>",
"      Absence of fetal thrombocytopenia",
"     </li>",
"     <li>",
"      Spontaneous resolution following delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of incidental thrombocytopenia of pregnancy, as with the diagnosis of ITP, requires the exclusion of other causes of thrombocytopenia. Thus, these two disorders may be impossible to accurately distinguish prior to delivery. As noted above, antiplatelet antibody testing does not reliably distinguish between these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This diagnostic dilemma may have important management implications related to the risk of fetal thrombocytopenia: thrombocytopenia does not occur in infants born to mothers with gestational thrombocytopenia, but may occur in up to 15 percent of infants born to mothers with ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced thrombocytopenia, including acute thrombocytopenia caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -containing beverages, foods, and herbal remedies, cannot be initially distinguished from ITP. The diagnosis of drug-induced disease requires resolution of the thrombocytopenia upon cessation of the implicated drug, typically within five days (",
"    <a class=\"graphic graphic_table graphicRef62516 \" href=\"UTD.htm?12/55/13182\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/70,95\">",
"     70,95",
"    </a>",
"    ]. Drug-induced thrombocytopenia, rather than ITP, should always be suspected in patients with recurrent, acute episodes of severe, symptomatic thrombocytopenia.",
"   </p>",
"   <p>",
"    Although drug-dependent antibodies can be documented by laboratory assays [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/96,97\">",
"     96,97",
"    </a>",
"    ], these assays are not routinely available in clinical laboratories and therefore cannot contribute to initial management decisions. Furthermore, tests for drug-dependent antibodies may be negative in patients with drug-induced thrombocytopenia. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The test may not be sufficiently sensitive to detect the drug dependent antibody.",
"     </li>",
"     <li>",
"      The antibody may only react with a metabolite of the drug. This may be seen in patients with thrombocytopenia caused by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"       \"Drug-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of published case reports of drug-induced thrombocytopenia presented a comprehensive database on the level of clinical evidence supporting a causal relationship of the drug to thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/70\">",
"     70",
"    </a>",
"    ]. This database, updated through October 2008, is available at &lt;",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    &gt;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral and bacterial infections commonly cause thrombocytopenia, which may be acute (eg, rubella, infectious mononucleosis, ehrlichiosis, hepatitis) or chronic and persistent (eg, HIV infection, HCV infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H2#H2\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Thrombocytopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H11#H11\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Autoimmune thrombocytopenic purpura and hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersplenism due to portal hypertension caused by chronic liver disease is characteristically associated with mild thrombocytopenia secondary to increased pooling of platelets in the splenic sinusoids [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/99\">",
"     99",
"    </a>",
"    ]. Diminished production of thrombopoietin may play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/100\">",
"     100",
"    </a>",
"    ]. Other signs of portal hypertension are typically present and the spleen is usually palpable; however, these signs are not apparent in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Myelodysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelodysplasia (MDS) in elderly patients may present initially with pure thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. This constitutes the rationale noted above for examination of the bone marrow in elderly patients with suspected ITP.",
"   </p>",
"   <p>",
"    This was shown in a retrospective study of interphase FISH analysis for del(20q) on thawed frozen bone marrow cell pellets from 23 adult patients with ITP. These patients had bone marrow examination performed mostly because of age &gt;60",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to respond to ITP therapy, including splenectomy. While bone marrow morphology, cellularity, and karyotype were normal in all of the cases, del(20q) was present in 12 (52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/92,101\">",
"     92,101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4008100#H4008100\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Complete blood count'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Congenital thrombocytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital, familial thrombocytopenia should be considered in patients with persistent thrombocytopenia unaffected by treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Although some reports suggest that the platelets in patients with ITP are larger than normal, truly giant platelets approaching the diameter of red blood cells do not occur in ITP. Their presence on the peripheral smear or automated cell counters strongly suggests the presence of congenital, familial thrombocytopenia (",
"    <a class=\"graphic graphic_picture graphicRef72433 \" href=\"UTD.htm?17/31/17911\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, in a study of 35 patients with inherited macrothrombocytopenias and 56 with ITP, a mean platelet volume &gt;12.4 fL had a sensitivity and specificity of 83 and 89 percent, respectively, in separating the former from the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among children, congenital thrombocytopenias are often initially misdiagnosed as ITP. Some of these are discussed elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H27#H27\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Abnormal platelet morphology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H26#H26\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Inherited disorders of platelet function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common of these and their typical clinical characteristics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      von Willebrand disease type 2B, with greater than expected bleeding for the degree of thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H24#H24\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Type 2B'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wiskott-Aldrich syndrome and its variant, X-linked thrombocytopenia, with small platelets and recurrent infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alport syndrome (hereditary nephritis) variants, with giant platelets, renal failure, and hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/106\">",
"       106",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      May-Hegglin anomaly, with giant platelets and D&ouml;hle bodies in granulocytes, and other manifestations of MYH9 gene mutations (the gene encoding the nonmuscle myosin heavy chain IIA) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/13/30938/abstract/107\">",
"       107",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H28#H28\">",
"       \"Approach to the adult patient with thrombocytopenia\", section on 'May-Hegglin anomaly'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fanconi syndrome, with short stature, anemia, and neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"       \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bernard-Soulier syndrome, with giant platelets and greater than expected bleeding for the degree of thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H30#H30\">",
"       \"Approach to the adult patient with thrombocytopenia\", section on 'Bernard-Soulier syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytopenia with absent radius (TAR) syndrome, with skeletal abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H28#H28\">",
"       \"Neonatal thrombocytopenia\", section on 'Thrombocytopenia-absent radius syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gray platelet syndrome, with giant platelets lacking alpha granules and predisposition to myelofibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H27#H27\">",
"       \"Congenital and acquired disorders of platelet function\", section on 'Giant platelet disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Acquired pure megakaryocytic aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the rare disorder acquired pure megakaryocytic aplasia (acquired amegakaryocytic thrombocytopenia) are clinically indistinguishable from patients with ITP, except for the absence of bone marrow megakaryocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"     \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information concerning thrombocytopenic conditions (ie, drug-induced, ITP, TTP-HUS, and thrombocytopenia in pregnancy) can be found on a database maintained by Dr. James N. George at the University of Oklahoma Health Sciences Center. This database is updated regularly and is available at",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/17/29970?source=see_link\">",
"       \"Patient information: Immune thrombocytopenia (ITP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no \"gold standard\" test that can establish the diagnosis of ITP. The diagnosis is in part one of exclusion, requiring that other causes of thrombocytopenia be ruled out (",
"    <a class=\"graphic graphic_table graphicRef77063 \" href=\"UTD.htm?39/51/40764\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A presumptive diagnosis of ITP is made when the history (eg, lack of ingestion of a drug that can cause thrombocytopenia), physical examination, complete blood count, and examination of the peripheral blood smear do not suggest other etiologies for the patient's",
"    <strong>",
"     isolated",
"    </strong>",
"    thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Recommended testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few diagnostic studies other than the history, physical examination, complete blood count, and examination of the blood smear are necessary. The only recommended further tests in such patients are HIV and HCV testing in all individuals. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     When to obtain hematologic consultation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with presumed ITP, severe thrombocytopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical bleeding, urgent hematologic consultation is most appropriate.",
"     </li>",
"     <li>",
"      For asymptomatic patients with modest degrees of thrombocytopenia, consultation is less urgent, but should be pursued in order to establish a clinical and laboratory baseline, should treatment be required in the future. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults\", section on 'General therapeutic principles'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/1\">",
"      George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/2\">",
"      Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/3\">",
"      British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/4\">",
"      Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/5\">",
"      Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/6\">",
"      Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/7\">",
"      Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:6511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/8\">",
"      Michel M, Lee K, Piette JC, et al. Platelet autoantibodies and lupus-associated thrombocytopenia. Br J Haematol 2002; 119:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/9\">",
"      Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/10\">",
"      Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/11\">",
"      Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011; 152:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/12\">",
"      Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006; 133:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/13\">",
"      Sood R, Wong W, Gotlib J, et al. Gene expression and pathway analysis of immune thrombocytopenic purpura. Br J Haematol 2008; 140:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/14\">",
"      DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol 2009; 146:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/15\">",
"      Mah&eacute;vas M, Chiche L, Uzunhan Y, et al. Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients. Medicine (Baltimore) 2011; 90:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/16\">",
"      Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/17\">",
"      Ustun C, Dainer P, Hendricks L, et al. Association of breast cancer and immune thrombocytopenic purpura. South Med J 2002; 95:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/18\">",
"      Peffault de Latour R, Des Guetz G, Laurence V, et al. Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases. Am J Clin Oncol 2004; 27:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/19\">",
"      Tfayli A, Vesely SK, George JN. Occurrence of immune thrombocytopenic purpura in patients with nonhematologic cancers: a systematic review of clinical evidence from case reports. Community Oncology 2008; 5:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/20\">",
"      Khasraw M, Baron-Hay S. Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? Ann Oncol 2009; 20:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/21\">",
"      Sukati H, Watson HG, Urbaniak SJ, Barker RN. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood 2007; 109:4528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/22\">",
"      Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008; 141:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/23\">",
"      Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 2009; 7:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/24\">",
"      Chong BH. Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments. J Thromb Haemost 2009; 7:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/25\">",
"      Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010; 148:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/26\">",
"      Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/27\">",
"      Semple JW. T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura. Transfus Apher Sci 2003; 28:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/28\">",
"      Olsson B, Andersson PO, Jern&aring;s M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/29\">",
"      Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev 2003; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/30\">",
"      Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/31\">",
"      Guo C, Chu X, Shi Y, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007; 27:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/32\">",
"      Sakakura M, Wada H, Tawara I, et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007; 120:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/33\">",
"      Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007; 79:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/34\">",
"      Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/35\">",
"      Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008; 112:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/36\">",
"      Audia S, Samson M, Guy J, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011; 118:4394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/37\">",
"      George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/38\">",
"      Fabris F, Scandellari R, Ruzzon E, et al. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 2004; 103:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/39\">",
"      Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 2005; 94:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/40\">",
"      Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/41\">",
"      Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/42\">",
"      Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/43\">",
"      Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009; 145:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/44\">",
"      Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/45\">",
"      Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010; 85:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/46\">",
"      Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/47\">",
"      Guthrie TH Jr, Brannan DP, Prisant LM. Idiopathic thrombocytopenic purpura in the older adult patient. Am J Med Sci 1988; 296:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/48\">",
"      Lusher JM, Iyer R. Idiopathic thrombocytopenic purpura in children. Semin Thromb Hemost 1977; 3:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/49\">",
"      Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966; 68:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/50\">",
"      Wright JF, Blanchette VS, Wang H, et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol 1996; 95:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/51\">",
"      Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol 1994; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/52\">",
"      Chiao EY, Engels EA, Kramer JR, et al. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med 2009; 169:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/53\">",
"      Zhang W, Nardi MA, Borkowsky W, et al. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009; 113:4086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/54\">",
"      Semple JW, Aslam R, Kim M, et al. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood 2007; 109:4803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/55\">",
"      Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007; 92:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/56\">",
"      Otton SH, Turner DL, Frewin R, et al. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999; 106:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/57\">",
"      Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/58\">",
"      CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/59\">",
"      Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011; 118:6299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/60\">",
"      Peng J, Friese P, Heilmann E, et al. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood 1994; 83:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/61\">",
"      Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/62\">",
"      Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/63\">",
"      McMillan R. The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura. Curr Hematol Rep 2005; 4:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/64\">",
"      Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/65\">",
"      Savage RA. Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin Pathol 1984; 81:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/66\">",
"      Vicari A, Banfi G, Bonini PA. EDTA-dependent pseudothrombocytopaenia: a 12-month epidemiological study. Scand J Clin Lab Invest 1988; 48:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/67\">",
"      Garcia Suarez J, Calero MA, Ricard MP, et al. EDTA-dependent pseudothrombocytopenia in ambulatory patients: clinical characteristics and role of new automated cell-counting in its detection. Am J Hematol 1992; 39:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/68\">",
"      Pegels JG, Bruynes EC, Engelfriet CP, von dem Borne AE. Pseudothrombocytopenia: an immunologic study on platelet antibodies dependent on ethylene diamine tetra-acetate. Blood 1982; 59:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/69\">",
"      Lam YK, Wong WC, Wong KF. Autoimmune thrombocytopenic purpura with spuriously normal platelet count and 'punch-hole' red cells. Br J Haematol 2007; 139:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/70\">",
"      George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/71\">",
"      Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/72\">",
"      Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer 1989; 64:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/73\">",
"      Menke DM, Colon-Otero G, Cockerill KJ, et al. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol 1992; 98:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/74\">",
"      Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood 1997; 89:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/75\">",
"      Lescale KB, Eddleman KA, Cines DB, et al. Antiplatelet antibody testing in thrombocytopenic pregnant women. Am J Obstet Gynecol 1996; 174:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/76\">",
"      Berchtold P, M&uuml;ller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997; 96:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/77\">",
"      Davoren A, Bussel J, Curtis BR, et al. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol 2005; 78:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/78\">",
"      McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003; 1:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/79\">",
"      George JN. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood 1990; 76:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/80\">",
"      Brighton TA, Evans S, Castaldi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/81\">",
"      Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med 2003; 114:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/82\">",
"      Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997; 24:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/83\">",
"      Kurata Y, Miyagawa S, Kosugi S, et al. High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/84\">",
"      Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84:4203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/85\">",
"      Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol 2005; 128:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/86\">",
"      Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 2006; 81:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/87\">",
"      Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008; 142:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/88\">",
"      Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/89\">",
"      Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004; 83:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/90\">",
"      Diz-K&uuml;&ccedil;&uuml;kkaya R, Hacihanefiolu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/91\">",
"      Jubelirer SJ, Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 2002; 8:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/92\">",
"      Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007; 139:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/93\">",
"      George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/94\">",
"      Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/95\">",
"      Rousan TA, Aldoss IT, Cowley BD Jr, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol 2010; 85:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/96\">",
"      Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/97\">",
"      Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/98\">",
"      Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am 2009; 23:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/99\">",
"      Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of \"hypersplenic\" thrombocytopenia. J Clin Invest 1966; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/100\">",
"      Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/101\">",
"      Soupir CP, Vergilio JA, Kelly E, et al. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol 2009; 144:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/102\">",
"      Najean Y, Lecompte T. Genetic thrombocytopenia with autosomal dominant transmission: a review of 54 cases. Br J Haematol 1990; 74:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/103\">",
"      Mhawech P, Saleem A. Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol 2000; 113:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/104\">",
"      Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/105\">",
"      Noris P, Klersy C, Zecca M, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 2009; 7:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/106\">",
"      Clare NM, Montiel MM, Lifschitz MD, Bannayan GA. Alport's syndrome associated with macrothrombopathic thrombocytopenia. Am J Clin Pathol 1979; 72:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/13/30938/abstract/107\">",
"      Seri M, Pecci A, Di Bari F, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82:203.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6676 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30938=[""].join("\n");
var outline_f30_13_30938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inciting events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      B and T cell responses in ITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS AND ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Onset after infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drug-associated immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Purine analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comparison with vasculitic purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparison with coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Correlation between bleeding and the platelet count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acquired platelet function abnormality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Making a presumptive diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antiplatelet antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinically apparent associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bone marrow aspiration and biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TTP-HUS and DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gestational thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Myelodysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Congenital thrombocytopenias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Acquired pure megakaryocytic aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Recommended testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      When to obtain hematologic consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6676|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/13/4318\" title=\"figure 1\">",
"      Age sex distrib ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/27/19901\" title=\"figure 2\">",
"      Platelet count and bleeding in ITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6676|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/8/10372\" title=\"picture 1\">",
"      Petechiae in immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/6/29794\" title=\"picture 2\">",
"      Petechiae in Henoch Schonlein purpura IgA vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 3\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 4\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/31/17911\" title=\"picture 5\">",
"      Giant platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6676|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 1\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/51/40764\" title=\"table 2\">",
"      Differential dx ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/55/13182\" title=\"table 3\">",
"      Drugs causing thrombopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29194?source=related_link\">",
"      Chronic refractory immune (idiopathic) thrombocytopenic purpura in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=related_link\">",
"      Evaluation and management of thrombocytopenia by primary care physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/17/29970?source=related_link\">",
"      Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=related_link\">",
"      Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_13_30939="Achilles tendon injuries";
var content_f30_13_30939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of Achilles tendon injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 1 Peritendinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute &lt;3 months duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic &gt;3 months duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 2 Pantendinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (peritendinitis and tendinosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute &lt;3 months duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic &gt;3 months duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 3 Tendinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rupture (no prodromal symptoms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic (neglected)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic (degenerative changes within an intact tendon: microtears)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type 4 Insertional tendinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericalcaneal bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pre-Achilles bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retrocalcaneal bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tuberosity impingement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Enthesopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30939=[""].join("\n");
var outline_f30_13_30939=null;
var title_f30_13_30940="CT for gallbladder polyps";
var content_f30_13_30940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Computed tomography of gallbladder polyps",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Histopathology",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        No. of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Plain CT",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Contrast CT",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Type of lesion",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Size of polyp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pedunculated",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sessile",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mass",
"       </td>",
"       <td class=\"subtitle2\">",
"        &lt;1 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        1-2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol polyp",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperplastic polyp",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenomyomatosis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoma",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenocarcinoma",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Furukawa, H, Takayasu, K, Mukai, K, et al, Hepatogastroenterology 1995; 42:800.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30940=[""].join("\n");
var outline_f30_13_30940=null;
var title_f30_13_30941="Irritant contact dermatitis clinical classification";
var content_f30_13_30941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical classification of irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        History",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute ICD",
"       </td>",
"       <td>",
"        <p>",
"         Acute exposure, usually accidental, to potent irritants (strong acids or alkalis)",
"        </p>",
"        <p>",
"         May develop within minutes after exposure to powerful irritants",
"        </p>",
"        <p>",
"         Nearly all exposed individuals develop skin lesions",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythema, edema, vesicles, bullae, epidermal necrosis",
"        </p>",
"        <p>",
"         Symptoms: stinging, burning, and pain",
"        </p>",
"        <p>",
"         Decrescendo phenomenon: the healing process begins soon after the removal of the offending substance",
"        </p>",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Delayed acute ICD",
"       </td>",
"       <td>",
"        <p>",
"         Delayed onset (8-24 hrs after exposure)",
"        </p>",
"        <p>",
"         Some chemicals, such as dithranol (anthralin), podophyllin, epichlorhydrin, propane sulfone, ethylene oxide, and benzalkonium chloride",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Similar clinical manifestation to acute ICD",
"        </p>",
"        <p>",
"         Patch testing: highly recommended for differential diagnosis from ACD",
"        </p>",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Irritant reaction",
"       </td>",
"       <td>",
"        <p>",
"         High-risk groups: wet-work workers such as hairdressers, food preparation workers, bar workers, new mothers, or cleaning personnel",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mild erythema, vesicles or erosions, dryness, chapping, and scaling",
"        </p>",
"        <p>",
"         Usually occur under occlusive areas",
"        </p>",
"        <p>",
"         May evolve to chronic cumulative ICD",
"        </p>",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Chronic cumulative ICD&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Most common type of ICD",
"        </p>",
"        <p>",
"         Repeated&nbsp;exposure to weak irritants (soaps, detergents, surfactants, solvents,&nbsp;or oils)",
"        </p>",
"        <p>",
"         High-risk groups: hairdressers, healthcare personnel, cleaning workers, and metal workers",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythema and dryness that progress to hyperkeratosis, fissuring, and lichenification",
"        </p>",
"        <p>",
"         Patch testing: highly recommended for differential diagnosis from ACD",
"        </p>",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Traumatic ICD",
"       </td>",
"       <td>",
"        Slower onset after laceration, burn, or acute ICD",
"       </td>",
"       <td>",
"        <p>",
"         Erythema, vesicles or papules, and scaling",
"        </p>",
"        <p>",
"         Prolonged healing time",
"        </p>",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Acneiform or pustular ICD",
"       </td>",
"       <td>",
"        <p>",
"         Rare, slow onset",
"        </p>",
"        <p>",
"         Tar, oils, naphthalenes, asphalt, chlorinated agents, or grease",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Papular or pustular lesions",
"        </p>",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Non-erythematous (suberythematous) irritation",
"       </td>",
"       <td>",
"        <p>",
"         Slow onset",
"        </p>",
"        <p>",
"         Surfactants in soaps, detergents, or cosmetics (cocoamidopropyl betaine, coconut diethanolamide)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Subjective discomfort such as stinging, itching, or burning, without visible clinical signs",
"        </p>",
"        <p>",
"         Histologic changes",
"        </p>",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sensory (subjective) irritation",
"       </td>",
"       <td>",
"        <p>",
"         Acute onset",
"        </p>",
"        <p>",
"         Mostly in middle-aged women",
"        </p>",
"        <p>",
"         Mainly cosmetic products containing&nbsp;lactic acid or sorbic acid",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lack of clinical signs of inflammation",
"        </p>",
"        <p>",
"         Subjective feeling of stinging, itching, and burning",
"        </p>",
"       </td>",
"       <td>",
"        Excellent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Friction irritation",
"       </td>",
"       <td>",
"        <p>",
"         Slow onset",
"        </p>",
"        <p>",
"         Repeated microtrauma and friction from&nbsp;handling wood, plants, coarse paper, or&nbsp;rock wool&nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        Lichenification, hyperkeratosis",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Asteatotic irritant dermatitis",
"       </td>",
"       <td>",
"        <p>",
"         Slow onset",
"        </p>",
"        <p>",
"         High risk group: elderly",
"        </p>",
"        <p>",
"         Mostly in winter",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythema, dry and cracked skin",
"        </p>",
"        <p>",
"         Intense itching",
"        </p>",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Watkins SA, Maibach HI. The hardening phenomenon in irritant contact dermatitis: An interpretative update. Contact Dermatitis 2009; 60:123.",
"       </li>",
"       <li>",
"        Amado A, Taylor JS, Sood A. Irritant Contact Dermatitis. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill Medical 2008. p.395.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30941=[""].join("\n");
var outline_f30_13_30941=null;
var title_f30_13_30942="Neck stiffness without fever in children";
var content_f30_13_30942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Neck stiffness or torticollis without fever in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 416px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SCM: sternocleidomastoid muscle; TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30942=[""].join("\n");
var outline_f30_13_30942=null;
var title_f30_13_30943="Anterior shoulder dislocation radiograph";
var content_f30_13_30943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior shoulder dislocation on the AP radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this AP x-ray the humoral head clearly lies outside the glenoid and below the coracoid process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_13_30943=[""].join("\n");
var outline_f30_13_30943=null;
